var title_f25_43_26288="RCDP type 2";
var content_f25_43_26288=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rhizomelic chondrodysplasia punctata type 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 319px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 5 year old female is one of twins with rhizomelic chondrodysplasia punctata type 2. This X-linked disorder is characterized by midface hypoplasia, high arched palate, ocular abnormalities and symmetric or asymmetric shortening of the long bones. The epiphyses and vertebral bodies are stippled. In this example, severe abnormalities of the cervical vertebral bodies have lead to occipitalization of C1, C2 instability and kyphosis of C5-6.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Jeanne Chow, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_43_26288=[""].join("\n");
var outline_f25_43_26288=null;
var title_f25_43_26289="Skin lesion in blastomycosis";
var content_f25_43_26289=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F83721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F83721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Verrucous skin lesion caused by Blastomyces dermatitidis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nonpainful, heaped-up lesion due to",
"    <em>",
"     Blastomyces dermatitidis",
"    </em>",
"    behind the ear of a 35-year-old man.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Bradsher RW, Bariola JR. Blastomycosis. In: Essentials of Clinical Mycology, 2nd ed, Kauffman CA, Pappas PG, Sobel JD, Dismukes WE (Eds), Springer, New York City 2011; with kind permission from Springer Science + Business Media B.V. Copyright &copy; 2011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_43_26289=[""].join("\n");
var outline_f25_43_26289=null;
var title_f25_43_26290="Cholesterol emboli retiform purpura";
var content_f25_43_26290=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F69150&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F69150&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Retiform purpura due to cholesterol emboli",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Retiform purpura (purpura in a pattern reminiscent of livedo reticularis) are present on the buttocks.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_43_26290=[""].join("\n");
var outline_f25_43_26290=null;
var title_f25_43_26291="Measles facial eruption";
var content_f25_43_26291=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F73806&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F73806&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Measles",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous erythematous macules are present on the face.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_43_26291=[""].join("\n");
var outline_f25_43_26291=null;
var title_f25_43_26292="Fire ant mounds in field";
var content_f25_43_26292=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F69747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F69747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fire ant mounds",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photograph shows multiple fire ant mounds in a field.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard D deShazo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_43_26292=[""].join("\n");
var outline_f25_43_26292=null;
var title_f25_43_26293="Etidronate: Pediatric drug information";
var content_f25_43_26293=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"10\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Etidronate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?22/23/22902?source=see_link\">",
"    see \"Etidronate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?43/37/44628?source=see_link\">",
"    see \"Etidronate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F13132424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Review of Long-term Bisphosphonate Efficacy for Osteoporosis",
"     </span>",
"     <span class=\"collapsible-date\">",
"      May 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       In response to serious postmarketing adverse reactions, including atypical femur fractures, osteonecrosis of the jaw, and esophageal cancer, and a paucity of long-term efficacy data, the FDA conducted a systematic review of long-term bisphosphonate therapy for osteoporosis. To date, randomized controlled trials have shown that bisphosphonate therapy is effective in preventing fractures in trials of 3- to 4-years duration. Therefore, to examine long-term efficacy, three long-term extension trials (involving postmenopausal women) ranging in a duration of treatment from 6-10 years were used in the FDA&rsquo;s analysis. Based on the available long-term clinical trial data, the FDA was unable to identify subgroups of patients who are more likely to benefit from therapy beyond 3-5 years. Continuation of treatment should be based on individual assessment of risks, benefits, and preferences of patients and their physicians.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Until further data are available, the data suggests patients at low risk for fracture (eg, younger patients without a fracture history and bone mineral density [BMD] approaching normal) may be good candidates for discontinuation of therapy after 3-5 years. Patients at increased risk, such as older patients with a history of fracture and a BMD in the osteoporotic range, may benefit from continued therapy.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further investigation into the risks and benefits of long-term therapy, the usefulness of markers of bone turnover or BMD in determining duration or interruption of therapy, and surveillance or fracture risk after therapy discontinuation are needed.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For additional information, please refer to file://www.nejm.org/doi/pdf/10.1056/NEJMp1202619.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F168977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Didronel&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F168978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Co-Etidronate;",
"     </li>",
"     <li>",
"      Mylan-Etidronate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1058536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Hypercalcemia",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Bisphosphonate Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1058529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/23/22902?source=see_link\">",
"      see \"Etidronate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Heterotopic ossification: Children and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Spinal cord injury: 20 mg/kg once daily (or in divided doses if GI discomfort occurs) for 2 weeks, then 10 mg/kg/day for 10 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Total hip replacement: 20 mg/kg/day 1 month before and 3 months after surgery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     This dosage when used in children for &gt;1 year has been associated with a rachitic syndrome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Paget's disease: Adults: Initial: 5-10 mg/kg/day (not to exceed 6 months) or 11-20 mg/kg/day (not to exceed 3 months). Doses &gt;20 mg/kg/day are",
"     <b>",
"      not",
"     </b>",
"     recommended. Higher doses should be used only when lower doses are ineffective or there is a need to suppress rapid bone turnover (eg, potential for irreversible neurologic damage) or reduce elevated cardiac output. Daily dose may be divided if adverse GI effects occur; courses of therapy should be separated by drug-free periods of at least 3 months.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Adult:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     S",
"     <sub>",
"      cr",
"     </sub>",
"     2.5-4.9 mg/dL: Use with caution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     S",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;5 mg/dL:",
"     <b>",
"      Not recommended",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F168955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as disodium: 200 mg, 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Didronel&reg;: 400 mg [DSC] [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F168939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1058539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral: Administer on an empty stomach with a full glass of plain water (6-8 oz), 2 hours before meals. Patients should be instructed to stay upright (not to lie down) after taking the medication.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1058532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature of 25&deg;C (77&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1058538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic treatment of Paget's disease of bone and prevention and treatment of heterotopic ossification following spinal cord injury or total hip replacement (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F169020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Etidronate may be confused with etomidate",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F169019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Bone pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Agranulocytosis, alopecia, amnesia, angioedema, arthralgia, arthritis, asthma  exacerbation, bone fracture, confusion, depression, esophageal cancer, esophagitis, follicular eruption, gastritis, glossitis, hallucination, headache, hypersensitivity reactions, leg cramps, leukopenia, macular rash, maculopapular rash, musculoskeletal pain (sometimes severe and/or incapacitating), osteomalacia, pancytopenia, paresthesia, peptic ulcer disease exacerbation, pruritus, Stevens-Johnson syndrome, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1058543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to etidronate, biphosphonates, or any component; clinically overt osteomalacia; patients with abnormalities of the esophagus which delay esophageal emptying, such as stricture or achalasia",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1058528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with restricted calcium and vitamin D intake; use with caution in patients with enterocolitis due to etidronate's potential to cause diarrhea particularly when using high dosages. Use with caution in patients with renal impairment; may require dose reduction. May cause irritation to upper gastrointestinal mucosa. Esophagitis, dysphagia, esophageal ulcers, esophageal erosions, and esophageal stricture (rare) have been reported with oral bisphosphonates; risk increases in patients unable to comply with dosing instructions. Use with caution in patients with dysphagia, esophageal disease, gastritis, duodenitis, or ulcers; may worsen underlying condition. Discontinue use if new or worsening symptoms develop.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Osteonecrosis of the jaw (ONJ) has been reported in patients receiving bisphosphonates, including etidronate. Risk factors include invasive dental procedures (eg, tooth extraction, dental implants, bone surgery), a diagnosis of cancer with concomitant chemotherapy or corticosteroids, poor oral hygiene, ill-fitting dentures, and comorbid disorders (anemia, coagulopathy, infection, pre-existing dental disease). Most reported cases occurred after I.V. bisphosphonate therapy; however, cases have been reported following oral therapy. A dental exam and preventative dentistry should be performed prior to placing patients with risk factors on chronic bisphosphonate therapy. The manufacturer&rsquo;s labeling states that discontinuing bisphosphonates in patients requiring invasive dental procedures may reduce the risk of ONJ; however, other experts suggest that there is no evidence that discontinuing therapy reduces the risk of developing ONJ (Assael, 2009). The benefit:risk must be assessed by the treating physician and/or dentist/surgeon prior to any invasive dental procedure. Patients developing ONJ while on bisphosphonates should receive care by an oral surgeon.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2868987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Response to therapy in Paget's disease may be slow in onset and continue for months after therapy is discontinued; do not increase dosage rapidly; treatment &gt;6 months or at doses &gt;20 mg/kg/day have been associated with osteomalacia and increased risk of fracture; long bones with predominantly lytic lesions may be prone to fracture, particularly in patients unresponsive to treatment; hyperphosphatemia may occur at doses of 10-20 mg/kg/day due to drug-related increases in the tubular reabsorption of phosphate; serum phosphate levels usually return to normal 2-4 weeks after discontinuation of therapy; monitor serum phosphate closely",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F168948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: May enhance the hypocalcemic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of antacids containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Magaldrate; Sodium Bicarbonate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral calcium supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Bisphosphonate Derivatives may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral iron supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Bisphosphonate Derivatives. Specifically, polyvalent cation-containing multivitamins may decrease the absorption of orally-administered bisphosphonate derivatives. Management: Avoid administration of polyvalent cation-containing multivitamins within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Bisphosphonate Derivatives may enhance the hypocalcemic effect of Phosphate Supplements.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May diminish the therapeutic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: Bisphosphonate Derivatives may enhance the adverse/toxic effect of SUNItinib. Specifically, the risk of osteonecrosis of the jaw may be increased.  Management: Monitor for development of osteonecrosis of the jaw in patients receiving sunitinib and bisphosphonates.  Avoid invasive dental procedures if possible.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F2868988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid concurrent administration with food high in calcium (eg, milk or milk products) which may decrease absorption; separate administration by at least 2 hours",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F168950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F168964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been reported in some but not all animal studies. There are no adequate and well-controlled studies in pregnant women. Bisphosphonates are incorporated into the bone matrix and gradually released over time. Theoretically, there may be a risk of fetal harm when pregnancy follows the completion of therapy. Based on limited case reports with pamidronate, serum calcium levels in the newborn may be altered if administered during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1058535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum calcium, phosphate, creatinine, BUN, alkaline phosphatase, 25(OH)D, pain",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1058527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreases bone resorption by inhibiting osteocystic osteolysis; decreases mineral release and matrix or collagen breakdown in bone",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1058541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of therapeutic effects: Within 1-3 months of therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Persists for 12 months without continuous therapy",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1058542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: &sim;3%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 1-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Primarily as unchanged drug in urine (50%) with unabsorbed drug eliminated in feces",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1058534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?43/37/44628?source=see_link\">",
"      see \"Etidronate: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with water or fruit juice on an empty stomach at least 30 minutes before any food. Do not take within 2 hours of food or dietary supplements containing calcium, iron, or magnesium. Consult prescriber to determine necessity of dietary supplements of calcium or increased dietary vitamin D. Certain dental procedures should be avoided if possible while taking this medication; consult prescriber.  May cause temporary nausea or vomiting (small, frequent meals may help), diarrhea, or bone pain (consult prescriber for analgesic). Report muscle twitching; unusual fever; convulsions; difficulty breathing; rash; bloody stool; pain in mouth, jaws, or teeth; acute or lasting bone pain; or other persistent adverse effects.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Assael LA, \"Oral Bisphosphonates as a Cause of Bisphosphonate-Related Osteonecrosis of the Jaws: Clinical Findings, Assessment of Risks, and Preventive Strategies,\"",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      , 2009, 67(5 Suppl):35-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/43/26293/abstract-text/19371813/pubmed\" id=\"19371813\" target=\"_blank\">",
"        19371813",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mital MA, Garber JE, and Stinson JT, \"Ectopic Bone Formation in Children and Adolescents With Head Injuries: Its Management,\"",
"      <i>",
"       J Pediatr Orthop",
"      </i>",
"      , 1987, 7(1):83-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/43/26293/abstract-text/3098781/pubmed\" id=\"3098781\" target=\"_blank\">",
"        3098781",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silverman SL, Hurvitz EA, Nelson VS, et al, \"Rachitic Syndrome After Disodium Etidronate Therapy in an Adolescent,\"",
"      <i>",
"       Arch Phys Med Rehabil",
"      </i>",
"      , 1994, 75(1):118-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/43/26293/abstract-text/8291954/pubmed\" id=\"8291954\" target=\"_blank\">",
"        8291954",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wysowski DK, \"Reports of Esophageal Cancer With Oral Bisphosphonate Use,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(1):89-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/43/26293/abstract-text/19118315/pubmed\" id=\"19118315\" target=\"_blank\">",
"        19118315",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13291 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-DEDEA7E9BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_43_26293=[""].join("\n");
var outline_f25_43_26293=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13132424\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168977\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168978\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058536\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058529\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168955\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168939\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058539\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058532\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058538\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169020\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169019\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058543\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058528\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2868987\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299302\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168948\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2868988\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168950\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168964\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058535\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058527\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058541\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058542\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058534\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13291\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13291|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/23/22902?source=related_link\">",
"      Etidronate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?43/37/44628?source=related_link\">",
"      Etidronate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_43_26294="Infil UC micropap variant";
var content_f25_43_26294=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F69301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F69301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Infiltrating urothelial carcinoma, micropapillary variant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 200px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A: The micropapillary variant of UC is characterized by fine papillae with high-grade cytologic features. Necrosis (lower right) is commonly present (20x). B: The papillae are usually contained within tissue retraction spaces, simulating lymphatic spaces (40x).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cristina Magi-Galluzzi, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_43_26294=[""].join("\n");
var outline_f25_43_26294=null;
var title_f25_43_26295="Pharmacology and toxicity of adrenal enzyme inhibitors and adrenolytic agents";
var content_f25_43_26295=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pharmacology and toxicity of adrenal enzyme inhibitors and adrenolytic agents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/43/26295/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/43/26295/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/43/26295/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/43/26295/contributors\">",
"     Lynnette K Nieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/43/26295/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/43/26295/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/43/26295/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several compounds inhibit adrenal steroidogenesis by interfering with one or more of the enzymes in the steroidogenic pathway (",
"    <a class=\"graphic graphic_figure graphicRef70372 \" href=\"UTD.htm?0/7/123\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef56781 \" href=\"UTD.htm?41/55/42879\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28391?source=see_link\">",
"     \"Adrenal steroid biosynthesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These compounds have been used to study the enzymes involved in steroid synthesis, to evaluate the hypothalamic-pituitary axis (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    ), and to treat some patients with endogenous excess of cortisol, androgen, or mineralocorticoid secretion.",
"   </p>",
"   <p>",
"    Indications for the use of these compounds include rapid control of severe hypercortisolism for any etiology of endogenous Cushing's syndrome, persistent hypercortisolism following pituitary surgery for Cushing's disease, and control of excess steroid production in adrenocortical carcinoma or ectopic ACTH syndrome.",
"   </p>",
"   <p>",
"    This topic provides an overview of the compounds that inhibit glucocorticoid biosynthesis or action. Their use in the treatment of Cushing's syndrome is reviewed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3081?source=see_link\">",
"     \"Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ADRENAL ENZYME INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     Ketoconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    block one or more of the enzymes in the cortisol and other steroid synthetic pathway. The subsequent decrease in cortisol secretion results in a compensatory rise in ACTH release for most of these compounds. This tends to override the drug-induced steroidogenic blockade. As a result, these drugs usually do not cause adrenal insufficiency in patients with normal hypothalamic-pituitary-adrenal function [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26295/abstract/1\">",
"     1",
"    </a>",
"    ], but can do so in those with limited pituitary or adrenal reserve. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3081?source=see_link&amp;anchor=H19#H19\">",
"     \"Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)\", section on 'Oral drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Aminoglutethimide, another drug with antisteroidogenic activity, is no longer available in any world market and will not be discussed further.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Ketoconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several azole-derived antifungal drugs have antisteroidogenic actions in humans, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    . Ketoconazole, but not fluconazole, is used clinically for the treatment of hypercortisolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3081?source=see_link&amp;anchor=H16432801#H16432801\">",
"     \"Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)\", section on 'Ketoconazole'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These compounds were developed because they inhibit a fungal CYP enzyme system.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     Ketoconazole",
"    </a>",
"    has effects on both androgen and cortisol synthesis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The endocrine effect first described with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      use was a decrease in androstenedione and testosterone production (due to potent inhibition of C17-20 desmolase), resulting in symptoms of androgen deficiency and gynecomastia [",
"      <a class=\"abstract\" href=\"UTD.htm?25/43/26295/abstract/2-4\">",
"       2-4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The effects of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      on cortisol synthesis result from its inhibition of CYP11A1 (side chain cleavage) and of CYP11B1 (conversion of 11-deoxycortisol to cortisol) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/43/26295/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. In many countries, it is the most commonly used enzyme inhibitor for treating patients with Cushing's syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3081?source=see_link&amp;anchor=H16432801#H16432801\">",
"       \"Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)\", section on 'Ketoconazole'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       Ketoconazole",
"      </a>",
"      requires an acid stomach for maximal absorption, which can be decreased by antacids and H2-antagonists [",
"      <a class=\"abstract\" href=\"UTD.htm?25/43/26295/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The side effects of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      are either due to inhibition of cortisol production (headache, sedation, fatigue, decreased appetite, nausea, and vomiting), or testosterone production (gynecomastia, decreased libido, and impotence). The latter adverse effects make this drug less useful for long-term treatment in male patients. Ketoconazole is also a rare cause of reversible hepatotoxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?25/43/26295/abstract/6\">",
"       6",
"      </a>",
"      ]. The clinical use and monitoring of ketoconazole are reviewed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3081?source=see_link&amp;anchor=H16432801#H16432801\">",
"       \"Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)\", section on 'Ketoconazole'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3081?source=see_link&amp;anchor=H1553178#H1553178\">",
"       \"Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)\", section on 'Suggested approach'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       Ketoconazole",
"      </a>",
"      inhibits CYP3A4 strongly and also CYP1A2 and CYP2C9, and has several important drug interactions. Fatal arrhythmias have been reported when ketoconazole has been used in combination with cisapride and it also increases",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/43/1717?source=see_link\">",
"       domperidone",
"      </a>",
"      plasma levels with potential risk to increase QT interval. Several drugs can be potentiated, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/45/2775?source=see_link\">",
"       felodipine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      , and other statins. It can reduce concentrations of aminoglycosides and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      . If used in the context of adrenal carcinoma, ketoconazole can increase toxicity of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , taxanes, and vinca alkaloids.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       Ketoconazole",
"      </a>",
"      is teratogenic and toxic to animal embryos, but has been used without harm to the fetus in the late stages of pregnancy. However, ketoconazole is not the treatment of choice during pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/39/4725?source=see_link&amp;anchor=H5#H5\">",
"       \"Cushing's syndrome in pregnancy\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Oral or intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      can also decrease excess cortisol production but there is very limited experience with this drug for the treatment of hypercortisolism [",
"      <a class=\"abstract\" href=\"UTD.htm?25/43/26295/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Metyrapone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     Metyrapone",
"    </a>",
"    is used for diagnostic testing of hypothalamic-pituitary-adrenal function, but it can also be given to control hypercortisolism in patients with Cushing's syndrome either of ACTH-independent or ACTH-dependent etiologies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/48/16135?source=see_link\">",
"     \"Metyrapone stimulation tests\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3081?source=see_link&amp;anchor=H16432822#H16432822\">",
"     \"Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)\", section on 'Metyrapone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     Metyrapone",
"    </a>",
"    is mainly an inhibitor of CYP11B1 (11-beta-hydroxylase), which catalyzes the final step in cortisol biosynthesis, conversion of 11-deoxycortisol to cortisol (",
"    <a class=\"graphic graphic_figure graphicRef56413 \" href=\"UTD.htm?42/12/43212\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26295/abstract/1\">",
"     1",
"    </a>",
"    ]. It also inhibits aldosterone secretion, presumably by inhibition of CYP11B2 (aldosterone synthase), but its effect on levels of potassium and sodium in blood and urine is mitigated by increased production of 11-deoxycorticosterone, which has mineralocorticoid activity; this can worsen salt retention and hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26295/abstract/8\">",
"     8",
"    </a>",
"    ]. Pituitary ACTH secretion increases in response to the reduction in cortisol levels; as a result, production of adrenal androgen precursors is also increased. If used long-term for management of hypercortisolism, metyrapone may result in acne",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hirsutism in female patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26295/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     Metyrapone",
"    </a>",
"    has been used in a small number of pregnant women with Cushing's syndrome without significant maternal or perinatal complications [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26295/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Given these limited data, the efficacy and safety of metyrapone in this setting remain unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/39/4725?source=see_link&amp;anchor=H5#H5\">",
"     \"Cushing's syndrome in pregnancy\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     Metyrapone",
"    </a>",
"    is widely used in certain countries such as the United Kingdom, but in North America, it is currently available via its new distributor, HRA Pharma, Paris, France (via its speciality pharmacy Direct Success Inc. with an order form available at",
"    <a class=\"external\" href=\"file://www.hra-pharma.com/\">",
"     www.hra-pharma.com",
"    </a>",
"    or by phone at 1-855-674-7663).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Etomidate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     Etomidate",
"    </a>",
"    , another imidazole derivative, is a parenterally administered drug that is given to sedate patients on mechanical ventilators in intensive care units. Like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    , its major adrenal action is to inhibit CYP11B1, but higher doses also inhibit CYP11A1 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26295/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. The net effect is inhibition of adrenocortical function [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26295/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It may be useful in critically ill patients with Cushing's syndrome or in those who cannot take oral medications.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     Etomidate",
"    </a>",
"    is infused intravenously in a low, nonhypnotic dose of 0.3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour. This dose lowers serum cortisol concentrations to the normal range (ie, 10",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    [28",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    within about 10 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26295/abstract/20\">",
"     20",
"    </a>",
"    ]. The main side effect is fatigue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H366108018\">",
"    <span class=\"h1\">",
"     ADRENOLYTIC AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Mitotane",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"     Mitotane",
"    </a>",
"    inhibits steroidogenesis but also has adrenolytic activity with longer term use. It acts on adrenocortical cell mitochondria to inhibit CYP11B1 (11-beta-hydroxylase) and cholesterol side-chain cleavage (CYP11A1) enzymes. It is metabolized into an acyl chloride that binds to important macromolecules in the mitochondria, causing mitochondrial destruction and necrosis of adrenocortical cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26295/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    has a cytotoxic effect on adrenal tissue in humans in both normal adrenals and in adrenocortical tumors. Mitotane can produce a \"medical\" adrenalectomy in patients with Cushing's disease, sometimes in association with pituitary radiotherapy. It is used most widely in patients with adrenal carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40762?source=see_link\">",
"     \"Treatment of adrenocortical carcinoma\"",
"    </a>",
"    .) It is also sometimes used in patients with ectopic corticotropin (ACTH) or corticotropin-releasing hormone (CRH) syndromes alone or in conjunction with one or more adrenal enzyme inhibitors to reduce cortisol synthesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1016?source=see_link\">",
"     \"Overview of the treatment of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"     Mitotane",
"    </a>",
"    has several extra-adrenal actions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It alters the metabolism of cortisol [",
"      <a class=\"abstract\" href=\"UTD.htm?25/43/26295/abstract/23\">",
"       23",
"      </a>",
"      ]. Cortisol is normally metabolized to compounds measurable in urine as 17-hydroxycorticosteroids (17-OHCS). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41319?source=see_link\">",
"       \"Measurement of urinary excretion of endogenous and exogenous glucocorticoids\"",
"      </a>",
"      .)&nbsp;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"       Mitotane",
"      </a>",
"      decreases the production of these metabolites by 50 to 80 percent; the excess cortisol is metabolized to 6-beta-hydroxycortisol, a more polar compound that is not measured in the 17-OHCS assay. This is important clinically because the efficacy of mitotane therapy should be assessed by measuring 24-hour urinary free cortisol excretion, not urinary 17-OHCS excretion, which is artifactually low with mitotane.",
"     </li>",
"     <li>",
"      It may cause new onset or worsening of hypercholesterolemia in patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      for long periods, perhaps because of inhibition of cholesterol oxidase [",
"      <a class=\"abstract\" href=\"UTD.htm?25/43/26295/abstract/24\">",
"       24",
"      </a>",
"      ]. Serum cholesterol concentrations may rise to as high as 560",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (14.5",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      after three or more months of therapy. Mitotane treatment should not be terminated in patients in whom it is effective, as therapy with HMG-CoA reductase inhibitors (statins) can decrease the high LDL cholesterol levels.",
"     </li>",
"     <li>",
"      It does not interfere with the excretion or assay of urinary cortisol and, therefore, urinary free cortisol measurements in",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      -treated patients accurately reflect integrated plasma free cortisol concentrations as they do in normal subjects. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41319?source=see_link\">",
"       \"Measurement of urinary excretion of endogenous and exogenous glucocorticoids\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It accelerates the metabolism of halogenated synthetic glucocorticoids such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"       fludrocortisone",
"      </a>",
"      , but has less effect on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      metabolism.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"       Mitotane",
"      </a>",
"      can",
"      <strong>",
"       increase",
"      </strong>",
"      the requirement for exogenous glucocorticoid in patients in whom adrenal insufficiency is induced who are given halogenated steroids as replacement therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?25/43/26295/abstract/25\">",
"       25",
"      </a>",
"      ]. Mineralocorticoid replacement is not always required since the zona glomerulosa is relatively spared, but can become required after longer exposure. Maintenance of normal mineralocorticoid activity is important because it puts the patient at lower risk for developing stress-related adrenal crisis.",
"     </li>",
"     <li>",
"      It increases serum levels of cortisol-binding globulin (CBG) and other hormone-binding globulins as much as two- to threefold; the levels return to normal within one year of discontinuing therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?25/43/26295/abstract/26\">",
"       26",
"      </a>",
"      ]. Total serum cortisol levels are elevated because of induction of CBG and should not be used for monitoring of cortisol secretion.",
"     </li>",
"     <li>",
"      The increase in CBG, and mainly alteration in cortisol and glucocorticoid metabolism, probably explains the need to increase the replacement dose of steroids that bind to CBG such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      , and their precursors, cortisone and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      It may also act on the pituitary by an unknown mechanism to inhibit ACTH secretion [",
"      <a class=\"abstract\" href=\"UTD.htm?25/43/26295/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In addition to its effect on CBG,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      increases serum concentrations of other binding globulins, including sex hormone-binding globulin (SHBG) and thyroid hormone-binding globulin (TBG). There may also be a direct inhibitory effect of mitotane on TSH secretion. Serum concentrations of both free testosterone and FT4 may be decreased. This issue is discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40762?source=see_link&amp;anchor=H23#H23\">",
"       \"Treatment of adrenocortical carcinoma\", section on 'Medical treatment of hypercortisolism'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"     Mitotane",
"    </a>",
"    destroys normal as well as neoplastic adrenal tissue; prolonged administration can result in primary adrenal insufficiency. Urinary free cortisol levels must be monitored and glucocorticoid replacement therapy instituted when appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40762?source=see_link\">",
"     \"Treatment of adrenocortical carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"     Mitotane",
"    </a>",
"    should",
"    <strong>",
"     not",
"    </strong>",
"    be given to pregnant women with Cushing's syndrome because permanent fetal adrenal damage may ensue [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26295/abstract/28\">",
"     28",
"    </a>",
"    ]. Women of reproductive age should be on some form of reliable contraception while receiving mitotane.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"     Mitotane",
"    </a>",
"    is taken up by fatty tissues and persists in plasma long after the drug is discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26295/abstract/29\">",
"     29",
"    </a>",
"    ]. As a result, the dose of glucocorticoid may have to be tapered to the usual replacement dose over a period of several weeks to months after the patient is cured and mitotane is discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;A review of dosing, efficacy, and side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    is found separately. Data on the use of mitotane in patients with adrenal carcinoma is also reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3081?source=see_link&amp;anchor=H6330785#H6330785\">",
"     \"Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)\", section on 'Mitotane'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40762?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of adrenocortical carcinoma\", section on 'Adjuvant mitotane'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     BLOCKADE OF CORTISOL ACTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H366107979\">",
"    <span class=\"h2\">",
"     Mifepristone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     Mifepristone",
"    </a>",
"    (RU-486) does not inhibit steroidogenesis, but instead antagonizes the peripheral actions of glucocorticoids and progestogens [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26295/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. It does so because it is a glucocorticoid and progesterone receptor antagonist.",
"   </p>",
"   <p>",
"    The major use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    is to terminate pregnancy, but it has, on occasion, been given to patients with Cushing's syndrome, particularly with Cushing's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26295/abstract/32,33\">",
"     32,33",
"    </a>",
"    ], ectopic ACTH syndrome, or adrenal carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26295/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. It also blocks the action of exogenous glucocorticoids, making it difficult to assess and treat the systemic peripheral glucocorticoid deficiency that it may induce. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/16/25866?source=see_link\">",
"     \"Therapeutic use and adverse effects of progesterone receptor antagonists and selective progesterone receptor modulators\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    for hypercortisolism is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3081?source=see_link&amp;anchor=H6330490#H6330490\">",
"     \"Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)\", section on 'Glucocorticoid-receptor antagonists (mifepristone)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H306069384\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several compounds inhibit adrenal steroidogenesis by interfering with one or more of the enzymes in the steroidogenic pathway (",
"      <a class=\"graphic graphic_figure graphicRef70372 \" href=\"UTD.htm?0/7/123\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef56781 \" href=\"UTD.htm?41/55/42879\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Indications for the use of these compounds include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Rapid control of severe hypercortisolism for any etiology of endogenous Cushing's syndrome",
"     </li>",
"     <li>",
"      Persistent hypercortisolism following pituitary surgery for Cushing's disease",
"     </li>",
"     <li>",
"      Control of excess steroid production in adrenocortical carcinoma or ectopic ACTH syndrome",
"     </li>",
"     <li>",
"      Second-line hormonal therapy for prostate cancer (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38520?source=see_link&amp;anchor=H15#H15\">",
"       \"Secondary endocrine therapies for castration resistant prostate cancer\", section on 'Ketoconazole'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       Ketoconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"       metyrapone",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"       etomidate",
"      </a>",
"      block one or more of the enzymes in the cortisol and other steroid synthetic pathway. The subsequent decrease in cortisol secretion results in a compensatory rise in ACTH release for most of these compounds. This tends to override the drug-induced steroidogenic blockade. As a result, these drugs usually do not cause adrenal insufficiency in patients with normal hypothalamic-pituitary-adrenal function, but can do so in those with limited pituitary or adrenal reserve. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Adrenal enzyme inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"       Mitotane",
"      </a>",
"      inhibits steroidogenesis but also has adrenolytic activity with longer term use. It is used most commonly for adrenal carcinoma, but is sometimes used for Cushing&rsquo;s syndrome. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Mitotane'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3081?source=see_link&amp;anchor=H6330785#H6330785\">",
"       \"Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)\", section on 'Mitotane'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40762?source=see_link&amp;anchor=H4#H4\">",
"       \"Treatment of adrenocortical carcinoma\", section on 'Adjuvant mitotane'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The major use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"       mifepristone",
"      </a>",
"      is to terminate pregnancy, but it has, on occasion, been given to patients with Cushing's syndrome, particularly with Cushing's disease, ectopic ACTH syndrome, or adrenal carcinoma. (See",
"      <a class=\"local\" href=\"#H366107979\">",
"       'Mifepristone'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/1\">",
"      LIDDLE GW, ISLAND D, LANCE EM, HARRIS AP. Alterations of adrenal steroid patterns in man resulting from treatment with a chemical inhibitor of 11 beta-hydroxylation. J Clin Endocrinol Metab 1958; 18:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/2\">",
"      Pont A, Williams PL, Azhar S, et al. Ketoconazole blocks testosterone synthesis. Arch Intern Med 1982; 142:2137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/3\">",
"      DeFelice R, Johnson DG, Galgiani JN. Gynecomastia with ketoconazole. Antimicrob Agents Chemother 1981; 19:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/4\">",
"      Sonino N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med 1987; 317:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/5\">",
"      Loose DS, Kan PB, Hirst MA, et al. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest 1983; 71:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/6\">",
"      McCance DR, Hadden DR, Kennedy L, et al. Clinical experience with ketoconazole as a therapy for patients with Cushing's syndrome. Clin Endocrinol (Oxf) 1987; 27:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/7\">",
"      Riedl M, Maier C, Zettinig G, et al. Long term control of hypercortisolism with fluconazole: case report and in vitro studies. Eur J Endocrinol 2006; 154:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/8\">",
"      COPPAGE WS Jr, ISLAND D, SMITH M, LIDDLE GW. Inhibition of aldosterone secretion and modification of electrolyte excretion in man by a chemical inhibitor of 11 beta-hydroxylation. J Clin Invest 1959; 38:2101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/9\">",
"      Verhelst JA, Trainer PJ, Howlett TA, et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol (Oxf) 1991; 35:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/10\">",
"      Schteingart DE. Drugs in the medical treatment of Cushing's syndrome. Expert Opin Emerg Drugs 2009; 14:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/11\">",
"      Feelders RA, Hofland LJ, de Herder WW. Medical treatment of Cushing's syndrome: adrenal-blocking drugs and ketaconazole. Neuroendocrinology 2010; 92 Suppl 1:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/12\">",
"      Aron DC, Schnall AM, Sheeler LR. Cushing's syndrome and pregnancy. Am J Obstet Gynecol 1990; 162:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/13\">",
"      Buescher MA, McClamrock HD, Adashi EY. Cushing syndrome in pregnancy. Obstet Gynecol 1992; 79:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/14\">",
"      Wagner RL, White PF, Kan PB, et al. Inhibition of adrenal steroidogenesis by the anesthetic etomidate. N Engl J Med 1984; 310:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/15\">",
"      Fry DE, Griffiths H. The inhibition by etomidate of the 11 beta-hydroxylation of cortisol. Clin Endocrinol (Oxf) 1984; 20:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/16\">",
"      de Jong FH, Mallios C, Jansen C, et al. Etomidate suppresses adrenocortical function by inhibition of 11 beta-hydroxylation. J Clin Endocrinol Metab 1984; 59:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/17\">",
"      Wagner RL, White PF. Etomidate inhibits adrenocortical function in surgical patients. Anesthesiology 1984; 61:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/18\">",
"      Fraser R, Watt I, Gray CE, et al. The effect of etomidate on adrenocortical function in dogs before and during hemorrhagic shock. Endocrinology 1984; 115:2266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/19\">",
"      Fellows IW, Bastow MD, Byrne AJ, Allison SP. Adrenocortical suppression in multiply injured patients: a complication of etomidate treatment. Br Med J (Clin Res Ed) 1983; 287:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/20\">",
"      Schulte HM, Benker G, Reinwein D, et al. Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects. J Clin Endocrinol Metab 1990; 70:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/21\">",
"      NELSON AA, WOODARD G. Severe adrenal cortical atrophy (cytotoxic) and hepatic damage produced in dogs by feeding 2,2-bis(parachlorophenyl)-1,1-dichloroethane (DDD or TDE). Arch Pathol (Chic) 1949; 48:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/22\">",
"      CUETO C, BROWN JH, RICHARDSON AP Jr. Biological studies on an adrenocorticolytic agent and the isolation of the active components. Endocrinology 1958; 62:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/23\">",
"      BLEDSOE T, ISLAND DP, NEY RL, LIDDLE GW. AN EFFECT OF O,P'-DDD ON THE EXTRA-ADRENAL METABOLISM OF CORTISOL IN MAN. J Clin Endocrinol Metab 1964; 24:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/24\">",
"      Yeung SC, Chiu AC, Vassilopoulou-Sellin R, Gagel RF. The endocrine effects of nonhormonal antineoplastic therapy. Endocr Rev 1998; 19:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/25\">",
"      Robinson BG, Hales IB, Henniker AJ, et al. The effect of o,p'-DDD on adrenal steroid replacement therapy requirements. Clin Endocrinol (Oxf) 1987; 27:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/26\">",
"      van Seters AP, Moolenaar AJ. Mitotane increases the blood levels of hormone-binding proteins. Acta Endocrinol (Copenh) 1991; 124:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/27\">",
"      Takamatsu J, Kitazawa A, Nakata K, et al. Does mitotane reduce endogenous ACTH secretion? N Engl J Med 1981; 305:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/28\">",
"      Leiba S, Weinstein R, Shindel B, et al. The protracted effect of o,p'-DDD in Cushing's disease and its impact on adrenal morphogenesis of young human embryo. Ann Endocrinol (Paris) 1989; 50:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/29\">",
"      Hogan TF, Citrin DL, Johnson BM, et al. o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement. Cancer 1978; 42:2177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/30\">",
"      Gaillard RC, Poffet D, Riondel AM, Saurat JH. RU 486 inhibits peripheral effects of glucocorticoids in humans. J Clin Endocrinol Metab 1985; 61:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/31\">",
"      Bertagna X, Basin C, Picard F, et al. Peripheral antiglucocorticoid action of RU 486 in man. Clin Endocrinol (Oxf) 1988; 28:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/32\">",
"      Bertagna X, Bertagna C, Laudat MH, et al. Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome. J Clin Endocrinol Metab 1986; 63:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/33\">",
"      Fleseriu M, Biller BM, Findling JW, et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab 2012; 97:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/34\">",
"      Castinetti F, Fassnacht M, Johanssen S, et al. Merits and pitfalls of mifepristone in Cushing's syndrome. Eur J Endocrinol 2009; 160:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26295/abstract/35\">",
"      Bilgin YM, van der Wiel HE, Fischer HR, De Herder WW. Treatment of severe psychosis due to ectopic Cushing's syndrome. J Endocrinol Invest 2007; 30:776.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 128 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C80C007BE0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_43_26295=[""].join("\n");
var outline_f25_43_26295=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H306069384\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ADRENAL ENZYME INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Ketoconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Metyrapone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Etomidate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H366108018\">",
"      ADRENOLYTIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Mitotane",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      BLOCKADE OF CORTISOL ACTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H366107979\">",
"      Mifepristone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H306069384\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/128\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/128|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/7/123\" title=\"figure 1\">",
"      Adrenal steroid synthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/55/42879\" title=\"figure 2\">",
"      Adrenal steroid inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/12/43212\" title=\"figure 3\">",
"      Action of metyrapone",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28391?source=related_link\">",
"      Adrenal steroid biosynthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/39/4725?source=related_link\">",
"      Cushing's syndrome in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41319?source=related_link\">",
"      Measurement of urinary excretion of endogenous and exogenous glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3081?source=related_link\">",
"      Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/48/16135?source=related_link\">",
"      Metyrapone stimulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1016?source=related_link\">",
"      Overview of the treatment of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38520?source=related_link\">",
"      Secondary endocrine therapies for castration resistant prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/16/25866?source=related_link\">",
"      Therapeutic use and adverse effects of progesterone receptor antagonists and selective progesterone receptor modulators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40762?source=related_link\">",
"      Treatment of adrenocortical carcinoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_43_26296="EEG Rhythmic midtemporal theta";
var content_f25_43_26296=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F70492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F70492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 574px\">",
"   <div class=\"ttl\">",
"    Rhythmical midtemporal theta of drowsiness",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 554px; height: 341px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rhythmical midtemporal theta of drowsiness (RMTD; see arrows); also known as psychomotor variant. This is a normal variant.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drs. Lawrence Hirsch and Hiba Arif.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_43_26296=[""].join("\n");
var outline_f25_43_26296=null;
var title_f25_43_26297="Fluconazole: Pediatric drug information";
var content_f25_43_26297=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluconazole: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"    see \"Fluconazole: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/4/29765?source=see_link\">",
"    see \"Fluconazole: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F171677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Diflucan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F171678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Fluconazole&reg;;",
"     </li>",
"     <li>",
"      CanesOral&reg;;",
"     </li>",
"     <li>",
"      CO Fluconazole;",
"     </li>",
"     <li>",
"      Diflucan&reg;;",
"     </li>",
"     <li>",
"      Dom-Fluconazole;",
"     </li>",
"     <li>",
"      Fluconazole Injection;",
"     </li>",
"     <li>",
"      Fluconazole Omega;",
"     </li>",
"     <li>",
"      Monicure;",
"     </li>",
"     <li>",
"      Mylan-Fluconazole;",
"     </li>",
"     <li>",
"      Novo-Fluconazole;",
"     </li>",
"     <li>",
"      PHL-Fluconazole;",
"     </li>",
"     <li>",
"      PMS-Fluconazole;",
"     </li>",
"     <li>",
"      PRO-Fluconazole;",
"     </li>",
"     <li>",
"      Riva-Fluconazole;",
"     </li>",
"     <li>",
"      Taro-Fluconazole;",
"     </li>",
"     <li>",
"      ZYM-Fluconazole",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1047385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antifungal Agent, Systemic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral, I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Daily dose of fluconazole is the same for oral and I.V. administration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Candidiasis, invasive (systemic):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Prophylaxis (Pappas, 2009; Wade, 2009): Dosing based on IDSA guidelines and a pharmacokinetic simulation. Duration should be guided by presence of risk factors. Further studies are needed to define optimal criteria and duration of fluconazole prophylaxis (Healy, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     GA &lt;30 weeks:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Initiation at PNA &lt;7 days [Dose selection may be directed by NICU-specific",
"     <i>",
"      Candida",
"     </i>",
"     sp. susceptibility (ie, use lower dose for an organism with an MIC &le;2 mcg/mL; neither dose has been studied for organisms with an MIC &gt;4 mcg/mL) (Pappas, 2009; Wade, 2009)]: 3 mg/kg/dose or 6 mg/kg/dose twice weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Initiation at PNA &ge;7 days: 3 mg/kg/dose once daily or 6 mg/kg/dose every 72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     GA 30-40 weeks: 6 mg/kg/dose every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment: 12 mg/kg/dose once daily for 21 days; gestational age not specified (Pappas, 2009). Others have recommended a loading dose of 25 mg/kg, followed by 12 mg/kg once daily; an evaluation of this dosing in five neonates (GA: 35-38 weeks; PNA: 16 days) showed all subjects reached target trough concentrations (&gt;8 mcg/mL) within 24 hours (Piper, 2011; Wade, 2008; Wade, 2009). Some experts have suggested 12 mg/kg/dose every 48 hours for PNA &lt;8 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Candidiasis, oral (thrush), treatment",
"     </b>",
"     (Pappas, 2009;",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009): Full-term:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PNA &le;14 days: Initial: 6 mg/kg/dose followed by 3 mg/kg/dose every 24-72 hours for  7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PNA &gt;14 days: Initial: 6 mg/kg/dose followed by 3 mg/kg/dose once daily for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cryptococcal meningitis:",
"     </b>",
"     PNA &gt;14 days:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acute: 12 mg/kg/dose followed by 6-12 mg/kg/day for 10-12 weeks after CSF culture becomes negative",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Relapse: 6 mg/kg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Candidiasis, prophylaxis: S",
"     <sub>",
"      Cr",
"     </sub>",
"     &ge;1.3 mg/dL: 6 mg/kg once weekly; once S",
"     <sub>",
"      Cr",
"     </sub>",
"     &le;1 mg/dL, then standard dosing can be resumed (Wade, 2009)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1047378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"      see \"Fluconazole: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral, I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Daily dose of fluconazole is the same for oral and I.V. administration; unless otherwise specified, therapy can be either oral or I.V. route:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      General dosing:",
"     </b>",
"     Manufacturer&rsquo;s labeling: Initial: 6-12 mg/kg/dose, followed by 3-12 mg/kg/dose once daily (maximum daily dose: 600 mg/",
"     <b>",
"      day",
"     </b>",
"     ); duration and dosage depends on severity of infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Candidiasis, esophageal; treatment:",
"     </b>",
"     6 mg/kg/dose on Day 1, followed by 3 mg/kg/dose once daily for at least 21 days and at least 2 weeks following symptom resolutions. In some cases, higher doses (up to 12 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     ) may be used (maximum daily dose: 400 mg/",
"     <b>",
"      day",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Candidiasis, esophageal (HIV-exposed/-positive)",
"     </b>",
"     (CDC, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Treatment: 6 mg/kg/dose on Day 1, followed by 3-6 mg/kg/dose once daily for 4-21 days (maximum daily dose: 400 mg/",
"     <b>",
"      day",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Relapse suppression: 3-6 mg/kg/dose once daily (maximum daily dose: 200 mg/",
"     <b>",
"      day",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Candidiasis, oropharyngeal; treatment:",
"     </b>",
"     6 mg/kg/dose on Day 1, followed by 3 mg/kg/dose once daily for at least 14 days (maximum daily dose:  200 mg/",
"     <b>",
"      day",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Candidiasis, oropharyngeal; treatment (HIV-exposed/-positive):",
"     </b>",
"     3-6 mg/kg/dose once daily (maximum daily dose: 400 mg/",
"     <b>",
"      day",
"     </b>",
"     ) for 7-14 days (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Candidiasis, systemic infection (invasive disease); treatment (neutropenic or non-neutropenic patients):",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Should only be used in a stable patient: 12 mg/kg/dose on Day 1 (maximum dose: 800 mg), followed by 12 mg/kg/dose once daily or 6 mg/kg/dose twice daily (maximum daily dose: 600 mg/",
"     <b>",
"      day",
"     </b>",
"     ); treatment duration: 2 weeks after clearance from blood and symptom resolution (Filioti, 2007; Pappas, 2009; Zaoutis, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Candidiasis, systemic infection (invasive disease); treatment (HIV-exposed/-positive):",
"     </b>",
"     5-6 mg/kg/dose twice daily  (maximum daily dose: 600 mg/",
"     <b>",
"      day",
"     </b>",
"     ) for minimum of 4 weeks; reserve for documented",
"     <i>",
"      C. albicans",
"     </i>",
"     or other susceptible species (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Coccidioidomycosis, meningeal infection, or in a stable patient with diffuse pulmonary or disseminated disease (HIV-exposed/-positive)",
"     </b>",
"     (CDC, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Treatment: 5-6 mg/kg/dose twice daily (maximum daily dose: 800 mg/",
"     <b>",
"      day",
"     </b>",
"     ), followed by chronic suppressive therapy (see below)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Relapse suppression: 6 mg/kg/dose once daily (maximum daily dose: 400 mg/",
"     <b>",
"      day",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Cryptococcal, CNS disease; treatment:",
"     </b>",
"     Acute therapy: 12 mg/kg/dose on Day 1, followed by 6 mg/kg/dose once daily; in some cases, doses as high as 12 mg/kg/dose once daily may be used dependent upon patient&rsquo;s response to therapy; treatment duration 10-12 weeks after CSF becomes culture negative (maximum daily dose: 800 mg/",
"     <b>",
"      day",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Cryptococcal, CNS disease (HIV-exposed/-positive):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Acute therapy, induction: 12 mg/kg /dose on Day 1, followed by 6-12 mg/kg/dose once daily (maximum daily dose: 800 mg/",
"     <b>",
"      day",
"     </b>",
"     ) plus flucytosine for at least 2 weeks until significant clinical improvement and negative CSF cultures  then begin consolidation therapy; reserve as alternate therapy when amphotericin (including lipid-based products) is not tolerated (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Consolidation therapy: 12 mg/kg/dose on Day 1, followed by 6-12 mg/kg/dose once daily (maximum daily dose: 800 mg/",
"     <b>",
"      day)",
"     </b>",
"     for a minimum of 8 weeks;",
"     <b>",
"      Note:",
"     </b>",
"     CSF cultures should be negative prior to initiating consolidation therapy (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Relapse suppression: 6 mg/kg/dose once daily (maximum  daily dose: 200 mg/",
"     <b>",
"      day",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Cryptococcal, localized (non-CNS), disseminated, or severe pulmonary disease (HIV-exposed/-positive)",
"     </b>",
"     (CDC, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Treatment: 12 mg/kg/dose on Day 1, followed by 6-12 mg/kg/dose once daily (maximum daily dose: 600 mg/",
"     <b>",
"      day",
"     </b>",
"     ); treatment duration variable and dependent upon infection site, severity, and clinical response; chronic suppressive therapy should be initiated upon treatment completion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Relapse suppression: 6 mg/kg/dose once daily (maximum daily dose: 200 mg/",
"     <b>",
"      day",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Histoplasmosis; relapse prevention (HIV-exposed/-positive):",
"     </b>",
"     3-6 mg/kg/dose once daily (maximum daily dose: 200 mg/",
"     <b>",
"      day",
"     </b>",
"     ) (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Prophylaxis, chemotherapy-induced neutropenia (including stem cell transplantation):",
"     </b>",
"     6 mg/kg/dose once daily during induction chemotherapy and period of neutropenia risk (maximum daily dose: 400 mg/",
"     <b>",
"      day",
"     </b>",
"     ) (Pappas, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Prophylaxis, postsolid organ transplant:",
"     </b>",
"     6 mg/kg/dose once daily for 14 days (maximum daily dose: 400 mg/",
"     <b>",
"      day",
"     </b>",
"     ) (Pappas, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      General dosing:",
"     </b>",
"     Manufacturer&rsquo;s labeling: Initial: 6-12 mg/kg/dose followed by 3-12 mg/kg/dose once daily (maximum daily dose: 600 mg/",
"     <b>",
"      day",
"     </b>",
"     ); duration and dosage depend on severity of infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Candidiasis, esophageal; treatment:",
"     </b>",
"     6 mg/kg/dose on Day 1, followed by 3 mg/kg/dose once daily for at least 21 days and at least 2 weeks following symptom resolutions. In some cases, higher doses (up to 12 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     ) may be used (maximum daily dose: 400 mg/",
"     <b>",
"      day",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Candidiasis, esophageal (HIV-exposed/-positive)",
"     </b>",
"     (CDC, 2009a):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Treatment: 100 mg/dose (up to 400 mg) once daily for 14-21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Relapse suppression: 100-200 mg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Candidiasis, oropharyngeal; treatment:",
"     </b>",
"     6 mg/kg/dose on Day 1, followed by 3 mg/kg/dose once daily for at least 14 days (maximum daily dose: 200 mg/",
"     <b>",
"      day)",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Candidiasis, oropharyngeal (HIV-exposed/-positive)",
"     </b>",
"     (CDC, 2009a):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Treatment: Oral: 100 mg/dose once daily for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Relapse suppression: Oral: 100 mg/dose three times weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Candidiasis, systemic infection (invasive disease); treatment (neutropenic or non-neutropenic patients):",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Should only be used in a stable patient: 12 mg/kg/dose on Day 1 (maximum dose: 800 mg) followed by 6 mg/kg/dose once or twice daily (maximum daily dose: 600 mg/",
"     <b>",
"      day",
"     </b>",
"     ); treatment duration: 2 weeks after clearance from blood and symptom resolution (Fioliti, 2007; Pappas, 2009; Zaoutis, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Candidiasis, vulvovaginal; uncomplicated (independent of HIV status):",
"     </b>",
"     Oral: 150 mg single dose (CDC, 2009a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Candidiasis, vulvovaginal; complicated (severe, recurrent) (HIV-exposed/-positive)",
"     </b>",
"     (CDC, 2009a):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Treatment: 150 mg/dose every 72 hours for 2-3 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Relapse suppression: Oral: 150 mg/dose once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Coccidioidomycosis, non-CNS disease (HIV-exposed/-positive)",
"     </b>",
"     (CDC, 2009a):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Prevention first episode: Oral: 400 mg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Treatment, mild infection or focal pneumonia: 400 mg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Maintenance therapy: Oral: 400 mg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Coccidioidomycosis, meningeal infection (HIV-exposed/-positive)",
"     </b>",
"     (CDC, 2009a):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Treatment: 400-800 mg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Maintenance therapy: Oral: 400 mg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Cryptococcal, CNS disease, treatment:",
"     </b>",
"     Acute therapy: 12 mg/kg/dose on Day 1, followed by 6 mg/kg/dose once daily; in some cases doses as high as 12 mg/kg/dose once daily may be used dependent upon patient&rsquo;s response to therapy; treatment duration 10-12 weeks after CSF becomes culture negative (maximum daily dose: 800 mg/",
"     <b>",
"      day",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Cryptococcal, CNS disease (HIV-exposed/-positive)",
"     </b>",
"     (CDC, 2009a):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Induction: 400 mg/dose once daily with amphotericin; if patient unable to tolerate amphotericin (or lipid product formulations) may use 400-800 mg/dose once daily with flucytosine for 4-6 weeks of therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Consolidation therapy [after at least 2 weeks of amphotericin induction therapy (ie, significant clinical improvement and negative CSF cultures)]: Oral: 400 mg/dose once daily for 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Maintenance therapy: Oral: 200 mg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Prophylaxis, chemotherapy-induced neutropenia (including stem cell transplantation):",
"     </b>",
"     6 mg/kg/dose once daily during induction chemotherapy and period of neutropenia risk (maximum daily dose: 400 mg/",
"     <b>",
"      day",
"     </b>",
"     ) (Pappas, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Prophylaxis, postsolid organ transplant:",
"     </b>",
"     6 mg/kg/dose once daily for 14 days (maximum daily dose: 400 mg/",
"     <b>",
"      day",
"     </b>",
"     ) (Pappas, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adult:",
"     <b>",
"      Usual dosage range:",
"     </b>",
"     150 mg once",
"     <b>",
"      or",
"     </b>",
"     200-800 mg/day; duration and dosage depend on severity of infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     No adjustment for vaginal candidiasis single-dose therapy; for multiple dosing, administer usual load then adjust daily doses as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt; 50 mL/minute: No adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;50 mL/minute (no dialysis): Administer 50% of recommended dose or administer every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Intermittent hemodialysis (IHD): Dialyzable (50%): May administer 100% of daily dose (according to indication) after each dialysis session. Alternatively, doses of 200-400 mg every 48-72 hours or 100-200 mg every 24 hours have been recommended (Heintz, 2009).",
"     <b>",
"      Note:",
"     </b>",
"     Dosing dependent on the assumption of 3 times/week, complete IHD sessions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1-2 L/hour and minimal residual renal function) and should not supersede clinical judgment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     CVVH: Loading dose of 400-800 mg followed by 200-400 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     CVVHD/CVVHDF: Loading dose of 400-800 mg followed by 400-800 mg every 24 hours (CVVHD or CVVHDF) or 800 mg every 24 hours (CVVHDF)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Higher maintenance doses of 400 mg every 24 hours (CVVH), 800 mg every 24 hours (CVVHD), and 500-600 mg every 12 hours (CVVHDF) may be considered when treating resistant organisms and/or when employing combined ultrafiltration and dialysis flow rates of &ge;2 L/hour for CVVHD/CVVHDF (Heintz, 2009; Trotman, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F171652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed iso-osmotic dextrose solution: 200 mg (100 mL); 400 mg (200 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed iso-osmotic sodium chloride solution: 100 mg (50 mL); 200 mg (100 mL); 400 mg (200 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed iso-osmotic sodium chloride solution [preservative free]: 200 mg (100 mL); 400 mg (200 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral: 10 mg/mL (35 mL); 40 mg/mL (35 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diflucan&reg;: 10 mg/mL (35 mL); 40 mg/mL (35 mL) [contains sodium benzoate, sucrose; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 50 mg, 100 mg, 150 mg, 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diflucan&reg;: 50 mg, 100 mg, 150 mg, 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F171637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1047389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer without regard to meals; shake suspension well before use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Administered by I.V. infusion over approximately 1-2 hours at a rate not to exceed 200 mg/hour; final concentration  2 mg/mL; for pediatric patients receiving doses &ge;6 mg/kg, administer I.V. infusion over 2 hours; pH: 4-8 (sodium chloride diluent); 3.5-6.5 (dextrose diluent)",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F171737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, aldesleukin, allopurinol, amifostine, amikacin, aminophylline, amiodarone, ampicillin/sulbactam, anidulafungin, aztreonam, benztropine, bivalirudin, caspofungin, cefazolin, cefepime, cefotetan, cefoxitin, chlorpromazine, cimetidine, cisatracurium, daptomycin, dexamethasone sodium phosphate, dexmedetomidine, diltiazem, dimenhydrinate, diphenhydramine, dobutamine, docetaxel, dopamine, doripenem, doxorubicin liposome, droperidol, etoposide phosphate, famotidine, fenoldopam, filgrastim, fludarabine, foscarnet, gallium nitrate, ganciclovir, gemcitabine, gentamicin, granisetron, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium phosphate, immune globulin intravenous, leucovorin calcium, linezolid, lorazepam, melphalan, meperidine, meropenem, metoclopramide, metronidazole, midazolam, morphine, nafcillin, nitroglycerin, ondansetron, oxacillin, paclitaxel, pancuronium, pemetrexed, penicillin G potassium, phenytoin, piperacillin/tazobactam, prochlorperazine edisylate, promethazine, propofol, quinupristin/dalfopristin, ranitidine, remifentanil, sargramostim, tacrolimus, telavancin, teniposide, theophylline, thiotepa, ticarcillin/clavulanate, tigecycline, tobramycin, vancomycin, vasopressin, vecuronium, vinorelbine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, ampicillin, calcium gluconate, cefotaxime, ceftriaxone, cefuroxime, chloramphenicol, diazepam, digoxin, erythromycin lactobionate, furosemide, haloperidol, hydroxyzine, imipenem/cilastatin, pantoprazole, pentamidine, sulfamethoxazole/trimethoprim.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Amphotericin B, anakinra, ceftazidime, clindamycin, piperacillin.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1047381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Store injection in glass at 5&deg;C to 30&deg;C (41&deg;F to 86&deg;F); store injection in Viaflex&reg; at 5&deg;C to 25&deg;C (41&deg;F to 77&deg;F). Do not freeze; do not unwrap unit until ready for use.  Incompatible with ampicillin, calcium gluconate, ceftazidime, cefotaxime, cefuroxime, ceftriaxone, clindamycin, furosemide, imipenem, ticarcillin, and piperacillin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Powder for oral suspension: Store dry powder at &lt;30&deg;C (&lt;86&deg;F). Following reconstitution, store at 5&deg;C to 30&deg;C (41&deg;F to 86&deg;F). Discard unused portion after 2 weeks. Do not freeze.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: Store at &lt;30&deg;C (&lt;86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1047388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of candidiasis (vaginal, oropharyngeal, esophageal, urinary tract infections, peritonitis, pneumonia, and systemic infections); cryptococcal meningitis; antifungal prophylaxis in allogeneic bone marrow transplant recipients (FDA approved in all ages); strains of",
"     <i>",
"      Candida",
"     </i>",
"     with decreased",
"     <i>",
"      in vitro",
"     </i>",
"     susceptibility to fluconazole are being isolated with increasing frequency; fluconazole is more active against",
"     <i>",
"      C. albicans",
"     </i>",
"     than other candidal strains like",
"     <i>",
"      C. parapsilosis",
"     </i>",
"     ,",
"     <i>",
"      C. glabrata",
"     </i>",
"     , and",
"     <i>",
"      C. tropicalis",
"     </i>",
"     ; for some infections, an alternative to amphotericin B in patients with pre-existing renal impairment or when requiring concomitant therapy with other potentially nephrotoxic drugs",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F171739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Fluconazole may be confused with flecainide, FLUoxetine, furosemide, itraconazole, voriconazole",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Diflucan&reg; may be confused with diclofenac, Diprivan&reg;, disulfiram",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Canesten (oral capsules) [Great Britain] may be confused with Canesten brand name for clotrimazole (various dosage forms) [multiple international markets]; Cenestin brand name estrogens (conjugated A/synthetic) [U.S., Canada]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F171736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angioedema (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, dysgeusia, dyspepsia, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, ALT increased, AST increased, hepatic failure (rare), hepatitis, jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic reactions (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Agranulocytosis, alopecia, cholestasis, diaphoresis, drug eruption, exanthematous pustulosis, fatigue, fever, hypercholesterolemia,  hypertriglyceridemia, hypokalemia, insomnia, leukopenia, malaise, myalgia, neutropenia, paresthesia, QT prolongation, seizure, somnolence, Stevens-Johnson syndrome, thrombocytopenia, torsade de pointes, toxic epidermal necrolysis, tremor, vertigo, weakness, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1047392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fluconazole, other azoles, or any component (cross-reaction with other azole antifungal agents may occur, but has not been established; use caution); concomitant administration with other drugs known to prolong the QT interval and  are metabolized via the enzyme CYP3A4 (eg, astemizole, cisapride, pimozide, quinidine); concomitant administration of terfenadine if fluconazole administered in multiple doses of &ge;400 mg",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1047377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and modify dosage in patients with impaired renal function. Use with caution in patients with hepatic dysfunction. The manufacturer reports rare cases of QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation and torsade de pointes associated with fluconazole use and advises caution in patients with concomitant medications or conditions which are arrhythmogenic. However, given the limited number of cases and the presence of multiple confounding variables, the likelihood that fluconazole causes conduction abnormalities appears remote.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Oral suspension may contain sucrose; avoid use in patients with hereditary fructose intolerance, glucose/galactose malabsorption, and sucrose-isomaltase deficiency.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1047376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serious (and rarely fatal) hepatic toxicity (eg, hepatitis, cholestasis, fulminant failure) due to fluconazole has been reported; usually is reversible upon discontinuation of therapy.  Patients who develop abnormal liver function tests during fluconazole therapy should be monitored closely for the development of more severe hepatic injury. Use with caution in patients with pre-existing hepatic impairment; monitor liver function closely and dosage adjustment may be warranted.  If clinical signs and symptoms consistent with liver disease develop that may be attributable to fluconazole, fluconazole should be discontinued. Rare cases of exfoliative skin disorders have been reported (including Stevens-Johnson syndrome and toxic epidermal necrolysis). Closely monitor patients who develop rashes during fluconazole therapy. Rare cases of anaphylaxis have been reported.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Fluconazole oral suspension contains sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; use fluconazole oral suspension containing sodium benzoate with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F171724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2C19 (strong), CYP2C9 (strong), CYP3A4 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F171646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfentanil: Fluconazole may decrease the metabolism of Alfentanil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Antifungal Agents (Azole Derivatives, Systemic) may diminish the therapeutic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Aprepitant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Fluconazole may increase the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: Fluconazole may increase the serum concentration of Avanafil.  Management: Limit avanafil to a maximum dose of 50 mg per 24-hour period in any patient who is also receiving a moderate inhibitor of CYP3A4 such as fluconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Benzodiazepines (metabolized by oxidation).  Management: The following combinations are specifically contraindicated: itraconazole with alprazolam, estazolam, oral midazolam, or triazolam; ketoconazole with alprazolam, estazolam, or triazolam.  Consider initial dose reductions of other benzodiazepines.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Quazepam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Bosentan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Antifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers.  Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Fluconazole may decrease the metabolism of Calcium Channel Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Fluconazole may increase the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cilostazol: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Cilostazol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cinacalcet: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Cinacalcet.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Cisapride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Citalopram: Fluconazole may increase the serum concentration of Citalopram.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: CYP2C19 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Fluconazole may decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Fluconazole may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Strong) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Strong) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Systemic): CYP2C9 Inhibitors (Strong) may increase the serum concentration of Diclofenac (Systemic).  Management: Consider using a lower dose of diclofenac when used together with a strong CYP2C9 inhibitor.  Arthrotec (diclofenac and misoprostol) labeling specifically recommends limiting the total daily dose to a maximum of 50 mg twice/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: May decrease the absorption of Antifungal Agents (Azole Derivatives, Systemic). Enteric coated didanosine capsules are not expected to affect these antifungals.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOCEtaxel: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of DOCEtaxel.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eletriptan: Fluconazole may decrease the metabolism of Eletriptan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Fluconazole may increase the serum concentration of Eplerenone.  Management: Reduce the starting dose of eplerenone to 25 mg/day; monitor patients closely for increased eplerenone effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Erlotinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eszopiclone: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Eszopiclone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This would be anticipated with itraconazole or ketoconazole. Etravirine may increase the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This would be anticipated with voriconazole. Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Etravirine. Management: Monitor for increased effects/toxicity of etravirine.  Antifungal dose adjustment may be needed for ketoconazole, itraconazole, or posaconazole but specific dosing guidelines are lacking.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluvastatin: Fluconazole may increase the serum concentration of Fluvastatin.  Management: Limit fluvastatin maximum  adult dose to 20 mg/day, and monitor for toxic effects of fluvastatin (e.g., myalgia, rhabdomyolysis, liver function test abnormalities), during concomitant treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Fosaprepitant. Specifically, concentrations of aprepitant are likely to be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Fluconazole may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Gefitinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This specifically applies to oral antifungal administration, and the interaction may be different depending on specific dosage form being used.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Imatinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Irbesartan: Fluconazole may decrease the metabolism of Irbesartan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Irinotecan: Antifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Irinotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine.  Management: In patients with a resting heart rate over 60 beats per minute receiving a moderate CYP3A4 inhibitor, ivabradine initiation at an adult dose of 2.5 mg twice daily may be considered.  Monitor heart rate closely under these circumstances.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Losartan: Fluconazole may decrease the metabolism of Losartan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: Fluconazole may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Macrolide Antibiotics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Fluconazole may increase the serum concentration of Methadone.  Management: Methadone dose reduction may be necessary when used with fluconazole.  With any concurrent use, monitor patients closely for evidence of methadone toxicities such as QT-prolongation or respiratory depression.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: Fluconazole may increase the serum concentration of Nevirapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: Fluconazole may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Fluconazole may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: Fluconazole may increase the serum concentration of Proton Pump Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Fluconazole may decrease the metabolism of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ramelteon: Fluconazole may decrease the metabolism of Ramelteon.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: Fluconazole may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Repaglinide.  Management: Concurrent use of an azole antifungal with both repaglinide and gemfibrozil should be avoided.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Rifamycin Derivatives. Only rifabutin appears to be affected.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: Fluconazole may decrease the metabolism of Rifamycin Derivatives. This appears only affect rifabutin. Rifamycin Derivatives may increase the metabolism of Fluconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saccharomyces boulardii: Antifungal Agents may diminish the therapeutic effect of Saccharomyces boulardii.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: Fluconazole may increase the serum concentration of Sildenafil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Fluconazole may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Fluconazole may increase the serum concentration of Sirolimus.  Management: Sirolimus dose adjustments will likely be needed when starting/stopping any azole antifungal.  Clinical data suggest sirolimus (adult) dose reductions of 50-90% will be needed when starting an azole antifungal, but specific guidelines are lacking.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solifenacin: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Solifenacin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Fluconazole may increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of SUNItinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Fluconazole may decrease the metabolism of Tacrolimus (Systemic).  Management: Monitor tacrolimus concentrations closely and adjust dose as necessary when concomitantly administered with fluconazole.  Reduced doses of fluconazole will likely be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Fluconazole may decrease the metabolism of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: Fluconazole may increase the serum concentration of Tadalafil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Fluconazole may increase serum concentrations of the active metabolite(s) of Temsirolimus.  Management: Consider temsirolimus dose reductions or alternatives to fluconazole.  Monitor sirolimus concentrations in all patients receiving fluconazole or any systemic azole antifungal.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Fluconazole may increase the serum concentration of Tipranavir.  Management: Limit fluconazole adult maximum dose to 200 mg/day in patients treated with tipranavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Fluconazole may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving moderate CYP3A4 inhibitors that strongly inhibit CYP2C19 (e.g., fluconazole, sitaxentan).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: Fluconazole may decrease the metabolism of Tolterodine. This is likely only of concern in CYP2D6-deficient patients (ie, \"poor metabolizers\")",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: Fluconazole may increase the serum concentration of Vardenafil.  Management: Limit vardenafil doses to a maximum of 5 mg per 24-hour period in patients receiving concurrent therapy with a moderate CYP3A4 inhibitor such as fluconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Fluconazole may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: Fluconazole may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Fluconazole may decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ziprasidone: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Ziprasidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: Fluconazole may increase the serum concentration of Zolpidem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F171648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (single dose for vaginal candidiasis)/D (all other indications) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F171662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal reproduction studies. When used in high doses, fluconazole is teratogenic in animal studies. Following exposure during the first trimester, case reports have noted similar malformations in humans when used in higher doses (400 mg/day) over extended periods of time (Aleck, 1997). Abnormalities reported include abnormal facies, abnormal calvarial development, arthrogryposis, brachycephaly, cleft palate, congenital heart disease, femoral bowing, thin ribs and long bones. Use of lower doses (150 mg as a single dose) does not suggest an increase risk to the fetus. Most azole antifungals, including fluconazole, are recommended to be avoided during pregnancy (Pappas, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1047384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic liver function (AST, ALT, alkaline phosphatase), renal function tests, serum potassium, CBC with differential, and platelet count",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1047375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with fungal cytochrome P450 sterol C-14 alpha-demethylation activity, decreasing ergosterol synthesis (principal sterol in fungal cell membrane) and inhibiting cell membrane formation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1047391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Well absorbed; food does not affect extent of absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely throughout body with good penetration into CSF, eye, peritoneal fluid, sputum, skin, and urine. Relative diffusion blood into CSF: Adequate with or without inflammation; CSF:blood concentration ratio: Independent of degree of meningeal inflammation: 70% to 80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 11% to 12%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: &gt;90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Premature neonates (GA: 26-29 weeks): 73.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PNA: 6 days: 53 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PNA: 12 days: 47 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     9 months to 13 years: Oral: 19.5-25 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     5-15 years: I.V.: 15-18 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Normal renal function: ~30 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 80% (unchanged in urine); 11% (metabolites in urine)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Hemodialysis: 3-hour session decreases plasma concentration 50%",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1047383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/4/29765?source=see_link\">",
"      see \"Fluconazole: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequent blood tests may be required. Maintain adequate hydration, unless instructed to restrict fluid intake. May cause headache, dizziness, drowsiness, nausea, vomiting, or diarrhea. Notify physician of persistent GI upset, urinary pattern changes, excessively dry eyes or mouth, changes in color of stool or urine, unusual bleeding or bruising, yellowing of skin and eyes, or severe skin rash. Counsel women of childbearing potential on the risk of birth defects with high-dose fluconazole use.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F13255706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Dosing equivalency suggested by the manufacturer's labeling:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pediatric patients 3 mg/kg = Adults 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pediatric patients 6 mg/kg = Adults 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pediatric patients 12 mg/kg = Adults 400 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/43/26297/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations From CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009a, 58(RR-4):1-207.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/43/26297/abstract-text/19357635/pubmed\" id=\"19357635\" target=\"_blank\">",
"        19357635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Como JA and Dismukes WE, \"Oral Azole Drugs as Systemic Antifungal Therapy,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 330(4):263-72.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Filioti J, Spiroglou K, Panteliadis CP, et al, \"Invasive Candidiasis in Pediatric Intensive Care Patients: Epidemiology, Risk Factors, Management, and Outcome,\"",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2007, 33(7):1272-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/43/26297/abstract-text/17503015/pubmed\" id=\"17503015\" target=\"_blank\">",
"        17503015",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goodman JL, Winston DJ, Greenfield RA, et al, \"A Controlled Trial of Fluconazole to Prevent Fungal Infections in Patients Undergoing Bone Marrow Transplantation,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1992, 326(13):845-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/43/26297/abstract-text/1542320 /pubmed\" id=\"1542320 \" target=\"_blank\">",
"        1542320",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Healy CM and Baker CJ, \"Fluconazole Prophylaxis in the Neonatal Intensive Care Unit,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2009, 28(1):49-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/43/26297/abstract-text/19106754/pubmed\" id=\"19106754\" target=\"_blank\">",
"        19106754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(5):562-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/43/26297/abstract-text/19397464/pubmed\" id=\"19397464\" target=\"_blank\">",
"        19397464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee JW, Seibel NL, Amantea M, et al, \"Safety and Pharmacokinetics of Fluconazole in Children With Neoplastic Diseases,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1992, 120(6):987-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/43/26297/abstract-text/1593362/pubmed\" id=\"1593362\" target=\"_blank\">",
"        1593362",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moncino MD and Gutman LT, \"Severe Systemic Cryptococcal Disease in a Child: Review of Prognostic Indicators Predicting Treatment Failure and an Approach to Maintenance Therapy With Oral Fluconazole,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1990, 9(5):363-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/43/26297/abstract-text/2352821/pubmed\" id=\"2352821\" target=\"_blank\">",
"        2352821",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pappas PG, Kauffman CA, Andes D, et al, \"Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 48(5):503-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/43/26297/abstract-text/19191635/pubmed\" id=\"19191635\" target=\"_blank\">",
"        19191635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Piper L, Smith PB, Hornik CP, et al, \"Fluconazole Loading Dose Pharmacokinetics and Safety in Infants,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2011, 30(5):375-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/43/26297/abstract-text/21085048/pubmed\" id=\"21085048\" target=\"_blank\">",
"        21085048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trotman RL, Williamson JC, Shoemaker DM, et al, &ldquo;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(8):1159-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/43/26297/abstract-text/16163635/pubmed\" id=\"16163635\" target=\"_blank\">",
"        16163635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Viscoli C, Castagnola E, Fioredda F, et al, \"Fluconazole in the Treatment of Candidiasis in Immunocompromised Children,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1991, 35(2):365-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/43/26297/abstract-text/2024968/pubmed\" id=\"2024968\" target=\"_blank\">",
"        2024968",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wade KC, Benjamin DK Jr, Kaufman DA, et al, \"Fluconazole Dosing for the Prevention or Treatment of Invasive Candidiasis in Young Infants,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2009, 28(8):717-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/43/26297/abstract-text/19593252/pubmed\" id=\"19593252\" target=\"_blank\">",
"        19593252",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wade KC, Wu D, Kaufman DA, et al, \"Population Pharmacokinetics of Fluconazole in Young Infants,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2008, 52(11):4043-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/43/26297/abstract-text/18809946/pubmed\" id=\"18809946\" target=\"_blank\">",
"        18809946",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zaoutis T, \"Candidemia in Children,\"",
"      <i>",
"       Curr Med Res Opin",
"      </i>",
"      , 2010, 26(7):1761-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/43/26297/abstract-text/20513207/pubmed\" id=\"20513207\" target=\"_blank\">",
"        20513207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13303 Version 52.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-2F5800EE8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_43_26297=[""].join("\n");
var outline_f25_43_26297=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171677\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171678\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047385\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442534\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047378\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171652\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171637\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047389\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171737\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047381\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047388\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171739\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171736\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047392\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047377\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047376\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171724\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171646\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171648\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171662\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047384\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047375\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047391\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047383\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13255706\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13303\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13303|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=related_link\">",
"      Fluconazole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/4/29765?source=related_link\">",
"      Fluconazole: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_43_26298="Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy";
var content_f25_43_26298=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/43/26298/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/43/26298/contributors\">",
"     Christine A Wanke, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/43/26298/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/43/26298/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/43/26298/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/43/26298/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/43/26298/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the availability of antiretroviral therapy, severe wasting and decreased levels of cholesterol were common metabolic abnormalities described in advanced AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With the introduction of effective antiretroviral therapy, descriptions of patients with body shape abnormalities, such as central fat accumulation and peripheral fat loss emerged [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/2\">",
"     2",
"    </a>",
"    ]. The term \"HIV-associated lipodystrophy syndrome\" was coined, but it soon became clear that some patients have pure lipoatrophy, others have fat accumulation, and a subset of patients have a mixed picture of both morphologic features. These morphologic abnormalities can also be associated with disorders in glucose and lipid metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. The metabolic disorders may also occur in the absence of body shape changes. The term \"metabolic syndrome\" refers specifically to the presence of three or more of the following findings: hypertriglyceridemia, low high-density lipoprotein (HDL) cholesterol, hypertension, abdominal obesity, and high serum glucose. While HIV-associated lipodystrophy is a term adapted specifically for HIV-infected individuals, metabolic syndrome is defined the same in HIV-infected individuals as the general population.",
"   </p>",
"   <p>",
"    Risk factors, clinical manifestations, screening, and diagnosis will be discussed here. The management and treatment of these patients is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44617?source=see_link\">",
"     \"Treatment of HIV-associated lipodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORICAL BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-associated lipodystrophy was initially described as a combination of fat loss in the limbs and fat accumulation in the abdomen [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/6\">",
"     6",
"    </a>",
"    ]. Studies of this syndrome were limited by lack of agreement on definitions and ways in which to study the various compartments. It became clear over time, however, that there is no single morphologic syndrome and it is more valid to consider its individual components separately, which often occur independently [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/7-12\">",
"     7-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This point was well illustrated in one study of 452 HIV-infected patients who were followed over one year to assess risk factors for progression of morphologic abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/13\">",
"     13",
"    </a>",
"    ]. Lipoatrophy was defined as a triceps skin-fold measurement less than the 10th percentile in the National Health and Nutrition Examination Survey for sex and age. Fat deposition was defined as a waist-to-hip ratio of &gt;0.95 for men and of &gt;0.85 for women. The study demonstrated the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The baseline prevalence for lipoatrophy, fat deposition, and a mixed picture was 35, 44, and 14 percent, respectively.",
"     </li>",
"     <li>",
"      The risk of developing new lipoatrophy was increased in patients with low baseline triceps skin-fold values and smaller hips; higher HIV RNA levels and use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      were also predictors of risk. Abacavir is not generally thought to induce lipoatrophy, but this analysis may represent attempts by clinicians to change antiretroviral therapy to agents thought less likely to contribute to lipoatrophy.",
"     </li>",
"     <li>",
"      In contrast, the risk of fat deposition was greater in women and occurred more frequently among those study participants who had higher levels of body fat or higher triglyceride levels at baseline.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, lipoatrophy and fat deposition appeared to be different syndromes with different risk factors. Furthermore, the prevalence of the combined syndrome differed from the prevalence of the two independent syndromes. The discussion below will address both lipoatrophy and fat accumulation as two separate and distinct entities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controversy exists about how frequently the syndrome occurs, with estimates ranging from 10 percent to more than 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. The wide variation in prevalence may be partly related to differences in geography, age, genetics, and lifestyle factors, as well as specific antiretroviral medications and duration of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/13,18,19\">",
"     13,18,19",
"    </a>",
"    ]. Wide variations in prevalence may also be related to definitions or methodology. In one study of 1035 participants, 50 percent had lipodystrophy with one-third reporting peripheral wasting, one-third with abdominal weight gain, and six percent with \"buffalo hump\" [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/17\">",
"     17",
"    </a>",
"    ]. However, this study was based on patient self-report, whereas others have been based on objective measurements, such as CT and DEXA scans.",
"   </p>",
"   <p>",
"    In an attempt to develop an objective case definition of lipodystrophy, investigators designed a case-control study with 1081 consecutive HIV-infected outpatients from 32 sites worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/20\">",
"     20",
"    </a>",
"    ]. A model including age, sex, duration of HIV infection, HIV disease stage, waist to hip ratio, anion gap, serum HDL cholesterol concentration, trunk to peripheral fat ratio, percentage leg fat, and intra-abdominal to extra-abdominal fat ratio had a sensitivity of 79 percent and a specificity of 80 percent for the diagnosis of lipodystrophy. However, models for pure lipoatrophy or pure lipodeposition could not be developed due to low prevalence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ADIPOKINES AND LIPODYSTROPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipodystrophy and metabolic abnormalities are commonly seen in HIV-infected patients. Adipocytes secrete hormones, such as adiponectin, leptin, and resistin, which are involved in metabolic pathways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In humans, decreased adiponectin levels are associated with insulin resistance and type 2 diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/21\">",
"       21",
"      </a>",
"      ]. In HIV-infected patients, adiponectin levels are decreased in patients with peripheral lipoatrophy and central lipohypertrophy [",
"      <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/22\">",
"       22",
"      </a>",
"      ]. It has been postulated that decreased adipocyte differentiation may lead to decreased adiponectin levels and insulin resistance in HIV-infected patients [",
"      <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Leptin levels are lower in the subgroup of patients with significant lipoatrophy compared with HIV-infected patients without lipoatrophy [",
"      <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/24\">",
"       24",
"      </a>",
"      ]. In mice, leptin deficiency is associated with insulin resistance. However, the absolute threshold of leptin deficiency that is associated with metabolic abnormalities is unclear.",
"     </li>",
"     <li>",
"      Treatment-naive patients who developed significant body composition and metabolic changes on ART were found to have a single nucleotide polymorphism in the resistin gene, which has been linked to diabetes in obese patients [",
"      <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether metabolic abnormalities are due to reduced adipose tissue mass or a change in hormone expression in adipose tissue is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/23\">",
"     23",
"    </a>",
"    ]. One study has also suggested that genetic polymorphisms involved in apoptosis and adipocyte metabolism may influence the emergence of lipoatrophy versus fat accumulation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/27\">",
"     27",
"    </a>",
"    ]. Another study examining the effect of mitochondrial haplogroups did not find any association with any specific changes in anthropomorphic measures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The contribution that antiretroviral therapy may play in the changes in this tissue compartment is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     LIPOATROPHY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipoatrophy (fat atrophy) involves the loss of subcutaneous fat in the face, arms, legs, abdomen,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    buttocks [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/13,18,29\">",
"     13,18,29",
"    </a>",
"    ]. In contrast to AIDS-associated wasting, lipoatrophy is distinguished by the preferential loss of fat tissue without substantial loss of lean tissue mass in patients who are clinically responding to ART [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/9,30\">",
"     9,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Atrophy of the buccal fat pads is of particular concern to patients since it gives the appearance of facial wasting and can have an impact on self-esteem [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/31\">",
"     31",
"    </a>",
"    ]. Various staging scales have been suggested for facial atrophy, but many of these are subjective [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. One scale, which incorporated the use of objective anatomic structures (eg, malar depression, buccal extension, melolabial ridge), demonstrated satisfactory interobserver variability [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lipoatrophy is also readily apparent in the extremities as veins and musculature become more prominent with the loss of supporting subcutaneous fat. Truncal subcutaneous lipoatrophy is often less noticeable than lipoatrophy elsewhere, especially if there is concomitant visceral fat deposition. In this situation, waist circumference may not change, as the intraabdominal volume may be increasing at the same time as the subcutaneous fat is decreasing (",
"    <a class=\"graphic graphic_figure graphicRef72033 \" href=\"UTD.htm?0/46/750\">",
"     figure 1",
"    </a>",
"    ). This may only be determined by CT or MRI scans, which can distinguish intraabdominal and subcutaneous fat; however, these scans are not readily available for diagnosis in the clinic as they are expensive and difficult to interpret.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV disease severity and host factors may interact to produce lipoatrophy. Increased age and lower CD4 cell counts at initiation of HIV therapy have been associated with self-reported lipoatrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/36\">",
"     36",
"    </a>",
"    ]. However, some studies using objective measurements of lipoatrophy have not confirmed a link between age or lower CD4 cell counts [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. The study discussed above suggests that higher baseline viral load, also a measure of disease severity, does predict lipoatrophy. Additional studies confirm that change in peripheral fat, over time, are linked to CD4 cell count and viral load [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/39\">",
"     39",
"    </a>",
"    ]. In fact, the FRAM study has suggested that lipoatrophy is the body shape change that is unique to patients infected with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/9,40\">",
"     9,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There has also been an epidemiological association between coinfection with Hepatitis C and the development of lipoatrophy in HIV-infected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/41\">",
"     41",
"    </a>",
"    ]. In the setting of hepatitis C and lipoatrophy, insulin resistance has been commonly documented.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Antiretroviral therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Nucleoside analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accumulating data suggest that exposure to certain NRTIs is the major factor associated with lipoatrophy, possibly due to NRTI-induced inhibition of mitochondrial DNA polymerase gamma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/9,13,14,42-46\">",
"     9,13,14,42-46",
"    </a>",
"    ]. Surgical biopsy specimens of subcutaneous adipose tissue in patients with lipoatrophy are characterized by mtDNA depletion, inflammation, and signs of apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Other researchers have only noted an association between lipoatrophy and duration of nucleoside analog use [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In vitro and in vivo studies suggest that thymidine analogs, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    in particular, play an important role in pathogenesis of lipoatrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/51-54\">",
"     51-54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one prospective, randomized, open trial, 237 patients initiating ART were assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      , both combined with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/51\">",
"       51",
"      </a>",
"      ]. At 96 weeks, a lower proportion of patients taking abacavir developed clinical signs of lipoatrophy (5 versus 38 percent) as assessed by anthropometric measurements.",
"     </li>",
"     <li>",
"      A metabolic substudy of a large clinical trial evaluating three initial regimens for treatment-naive HIV-infected patients evaluated long-term changes in subcutaneous tissue using skinfold measurements in 308 participants [",
"      <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/52\">",
"       52",
"      </a>",
"      ]. In this prospective, nonrandomized evaluation, similar losses of subcutaneous tissue were noted in treatment arms containing either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      plus lamivudine. In contrast, patients in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      plus lamivudine arm had tissue gains over the 36-month period of follow-up.",
"     </li>",
"     <li>",
"      DEXA scans were performed every 16 weeks on a subset of 157 antiretroviral-naive patients who were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"       nelfinavir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      , or both, combined with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"       didanosine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/53\">",
"       53",
"      </a>",
"      ]. After week 32, limb fat declined by 2 percent per year in the",
"      <span class=\"nowrap\">",
"       zidovudine/lamivudine",
"      </span>",
"      arm compared with 19 percent per year in the",
"      <span class=\"nowrap\">",
"       didanosine/stavudine",
"      </span>",
"      arm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies have suggested that although NRTI use contributes to fat wasting, protease inhibitors may act synergistically with NRTIs [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. However, therapy with protease inhibitors alone does not appear to lead to lipoatrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the metabolic substudy of ACTG 5142, which examined varying strategies for the treatment-naive patient, the incidence of lipodystrophy was significantly higher in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    plus two NRTIs group than in the lopinavir plus two NRTIs or efavirenz plus lopinavir groups (32 versus 17 versus 9 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/56\">",
"     56",
"    </a>",
"    ]. The association of lipoatrophy with efavirenz use was mainly in combination with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    , but not with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    . Other studies have suggested that the role of efavirenz in the development of lipodystrophy is minimal and mainly directed by the nucleoside analogs that form the backbone [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link&amp;anchor=H11#H11\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\", section on 'Efficacy by drug class'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Screening and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient self-report may be an early and the best indicator of body shape changes. Anthropometric evaluations of limb circumferences and skin folds provide data regarding body shape, but can vary depending on the evaluator. Objective quantification of fat can be obtained by CT, MRI, and DEXA scanning, but are usually limited to research venues and offer no additional benefit to patient self-report and physical examination [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/12\">",
"     12",
"    </a>",
"    ], as they are difficult to interpret and norms are not available. There are no widely accepted objective techniques for assessing malar atrophy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     FAT ACCUMULATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in lipoatrophy, there are conflicting data about the precise prevalence of this part of the syndrome, in part depending on definitions, but estimates of 35 to 40 percent in HIV-infected individuals are likely realistic [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, one study that compared HIV-infected patients with controls, (Fat Redistribution and Metabolic Abnormalities in HIV or FRAM study) suggested that overall fat deposition was no more common in HIV-infected individuals than it was in HIV-negative controls. It also showed that the prevalence of cervical dorsal fat pad (buffalo hump) was similar in HIV-infected and uninfected controls; however, the size of the buffalo hump may be significantly greater in HIV-infected individuals.",
"   </p>",
"   <p>",
"    The authors suggested that fat deposition in HIV-infected patients may reflect the epidemic of obesity that is occurring in the general population, rather than an effect of HIV infection or antiretroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/9,40,58\">",
"     9,40,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study of more than 1200 women demonstrated that BMI and waist and hip circumference increased over five years among HIV-seronegative women (n = 266), but remained stable in HIV-infected women (n = 942) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/59\">",
"     59",
"    </a>",
"    ]. Although the study participants had generally mild immunosuppression, these results suggest that HIV infection, or other related factors, interfere with the usual age-associated increases in weight and waist circumference seen in women in the United States. However, in the Multicenter AIDS Cohort Study, HIV-infected men had more rapid increases in waist circumference over five years than did HIV-seronegative men [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/50\">",
"     50",
"    </a>",
"    ]. ART use was not associated with the clinical findings in either study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fat accumulation, or lipodeposition, has been described since the introduction of HAART [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/3,13,29,60-62\">",
"     3,13,29,60-62",
"    </a>",
"    ]. Abdominal fat accumulation is an excess of visceral adipose tissue (VAT) that results in an increase in abdominal girth. \"Buffalo hump\" results from an accumulation of fat in the dorsocervical area. Both men and women may develop deposition of extra breast fat or symmetrical deposits of subcutaneous fat nodules on their trunk and extremities (eg, lipomas).",
"   </p>",
"   <p>",
"    In many cases, it may be difficult to distinguish this syndrome from simple obesity, in which visceral fat is also accompanied by increased amounts of subcutaneous fat in the abdominal wall. The distinguishing feature of HIV-associated lipodystrophy is that visceral fat deposition is accompanied by normal or decreased (but not increased) amounts of subcutaneous fat. This distinction may be difficult to determine without the use of CT or MRI imaging to quantify the amount of fat in various compartments (",
"    <a class=\"graphic graphic_figure graphicRef72033 \" href=\"UTD.htm?0/46/750\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    One study of HIV-seropositive and HIV-seronegative men demonstrated that changes in waist circumference increased at the same rate in all groups, irrespective of HIV status or ART received [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/63\">",
"     63",
"    </a>",
"    ]. These results were similar to another study in HIV-seropositive and HIV-seronegative women [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/19\">",
"     19",
"    </a>",
"    ]. The",
"    <span class=\"nowrap\">",
"     waist/hip",
"    </span>",
"    ratio may be a more informative measure due to the independent effects of lipoatrophy and lipodeposition on metabolic parameters, such as insulin resistance (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Insulin resistance'",
"    </a>",
"    below). However, the ratio of waist and hip measure needs to be interpreted with caution as the ratio may change (or may not change) because of changes in each of the measures included. For example, if the waist increases and the hips do not, the ratio increases; if the waist does not change but the hips decrease, the ratio would also increase.",
"   </p>",
"   <p>",
"    \"Pinchable\" fat at the waistline is a helpful clinical distinguishing feature of subcutaneous fat. An HIV-infected patient with both lipoatrophy and fat deposition would have minimal \"pinchable\" fat at the waistline with an increased waist circumference, since the visceral or intraabdominal fat is not palpable externally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors associated with the development of fat deposition include: increasing age, female sex, amount of body fat, and longer duration of ART (which may be a surrogate for longer duration of HIV infection) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/50\">",
"     50",
"    </a>",
"    ]. These factors differ from the predictors of lipoatrophy also suggesting that the two body shape syndromes are not necessarily linked pathogenetically [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Lipoatrophy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Studies that have examined the diet of HIV-infected individuals with and without visceral adiposity have suggested that poorer quality of diet, as measured by amount of fiber, are associated with the occurrence of fat deposition [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The development of visceral obesity, insulin resistance, and atherogenic lipid profiles raises concern regarding a potential increased risk of cardiovascular disease in HIV-infected individuals, since these are all well-established risk factors for coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26650?source=see_link\">",
"     \"Epidemiology of cardiovascular disease and risk factors in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Antiretroviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of protease inhibitor therapy was initially thought to lead to the development of fat deposition [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/29,60,68\">",
"     29,60,68",
"    </a>",
"    ]. However, in studies that have replaced protease inhibitor agents with alternative antiretroviral therapy, (eg, non-nucleoside reverse transcriptase inhibitors), there has been no observed decrease in visceral fat [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. In addition, since its original description, lipodystrophy has also been described in patients on antiretroviral therapy who were never exposed to a protease inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/30,62\">",
"     30,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 422 antiretroviral therapy-naive patients initiating therapy, there was no difference in the development of regional fat in any of the three treatment arms utilizing a PI, a NNRTI, or a PI plus NNRTI strategy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Screening and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a wide range of screening techniques for abdominal obesity. Simple measures include measurement of the waist circumference. An abdominal circumference &gt;102 cm for men and &gt;88 cm for women is considered abnormal, and considered more accurate than a",
"    <span class=\"nowrap\">",
"     waist/hip",
"    </span>",
"    circumference ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/67\">",
"     67",
"    </a>",
"    ]. Quantitative measurements of visceral adipose tissue by CT or MRI are usually done in research trials only. DEXA cannot distinguish between visceral and subcutaneous adipose tissue and is not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     INSULIN RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few data about insulin and glucose status in HIV-infected individuals prior to the advent of ART. Most data are related to studies done in the post-ART era.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Definitions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disorders of glucose metabolism are defined as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/13,58,72\">",
"     13,58,72",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impaired glucose tolerance: blood sugar of 140 to 199",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      two hours after receipt of a 75 g loading dose of glucose during an oral glucose tolerance test.",
"     </li>",
"     <li>",
"      Impaired fasting glucose: fasting blood glucose 100 to 125",
"      <span class=\"nowrap\">",
"       mg/dL.",
"      </span>",
"     </li>",
"     <li>",
"      Diabetes: fasting blood sugar of &gt;126",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or a two-hour OGTT of &gt;200.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of impaired glucose tolerance or impaired fasting glucose tolerance suggests that insulin resistance may be present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=see_link\">",
"     \"Diagnosis of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Measures of insulin resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurements of insulin resistance range from simple fasting glucose levels, insulin concentration measurements, and glucose tolerance tests, to more invasive interventions, such as euglycemic insulin clamps, which are performed as part of clinical studies. However, fasting blood insulin and glucose levels correlate well with assessments made by this technique [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/73\">",
"     73",
"    </a>",
"    ]. One of the research questions of interest is whether insulin resistance in HIV-infected individuals is central or peripheral, and whether either mechanism is more closely associated with lipoatrophy or visceral fat deposition.",
"   </p>",
"   <p>",
"    Study data are frequently presented as a calculation of insulin sensitivity by the homeostasis model assessment of insulin resistance (HOMA) or the quantitative insulin sensitivity check index (QUICKI), which utilize fasting glucose and fasting insulin measurements. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of glucose intolerance in the HIV-seropositive population is unclear. The development of frank diabetes in HIV infection is unusual, although it may be more common than in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/74\">",
"     74",
"    </a>",
"    ]. In one study of 422 antiretroviral therapy-naive patients who were randomly assigned to three different ART strategies, insulin resistance increased over time and was similar in all treatment arms [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/71\">",
"     71",
"    </a>",
"    ]. In another study, 1263 HIV-infected Italian patients had a significantly greater prevalence of impaired fasting glucose compared to 2051 controls [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies examining the prevalence and predictors of glucose intolerance and insulin resistance, and their association with ART, suggest that obesity, gender, non-white race, family history of diabetes, and older age are all predictors of insulin intolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/76\">",
"     76",
"    </a>",
"    ]. One prospective study of 1614 HIV-infected women in the Women's Interagency HIV Study also suggested an association of insulin resistance and cumulative exposure to NRTI use, especially",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hepatitis C has been reported as an epidemiologic link with diabetes in the general population and in HIV infected patients as well [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/78\">",
"     78",
"    </a>",
"    ]. This may be an important etiologic factor to consider in light of the high rates of HIV and HCV coinfection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Antiretroviral therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Protease inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concerns have arisen that chronic administration of specific antiretroviral agents, particularly protease inhibitors (PIs), may be associated with abnormalities in glucose tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/80\">",
"     80",
"    </a>",
"    ]. In vitro cell culture systems suggest that PIs can inhibit the uptake of glucose into cells by interfering with the GLUT 4 glucose transporter [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Firm conclusions about the role of protease inhibitors cannot be established at this time due to relative lack of data. One of the other problems of sorting out a \"class effect\" is that most patients are taking combination antiretroviral therapy regimens. One four-year prospective study examined the incidence of diabetes in women taking antiretroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/82\">",
"     82",
"    </a>",
"    ]. The treatment categories were as follows: 609 women on protease inhibitors (PI); 932 women on nucleoside analog therapy alone; 816 women on no ART and 350 HIV-uninfected women. PI use was associated with a threefold increase in the risk of incident diabetes.",
"   </p>",
"   <p>",
"    In studies done in HIV-negative control subjects, treatment doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    and lopinavir were associated with the development of abnormalities in glucose metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/83-85\">",
"     83-85",
"    </a>",
"    ]. These abnormalities were more severe in individuals who have strong family histories of glucose intolerance, suggesting that a genetic component may also contribute to these observations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. Two other studies in healthy volunteers suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    has little effect on insulin sensitivity compared to lopinavir or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/85,86\">",
"     85,86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Nucleoside analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cumulative exposure to nucleoside analogs was associated with insulin resistance in one prospective cohort [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/87\">",
"     87",
"    </a>",
"    ]. In this study, 533 HIV-infected patients and 755 HIV-seronegative controls were evaluated from 1999 to 2003 for fasting blood glucose and insulin levels. Of all the antiretroviral agents examined,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    was associated with the highest risk of hyperinsulinemia (odds ratio, 1.2).",
"   </p>",
"   <p>",
"    Fat redistribution may also contribute to insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. In a study of 41 HIV-seropositive men (20 with lipodystrophy and 20 without) and 20 HIV-seronegative controls, waist to hip ratio was superior to other body-composition measures in predicting fasting hyperinsulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/88\">",
"     88",
"    </a>",
"    ]. Another study suggested that the severity of lipoatrophy, among patients taking either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    , was associated with an increased risk of insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Screening and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A fasting blood glucose (FBG) level should be obtained before and six months after initiation of any new HIV treatment regimen. If the test results are normal, we suggest monitoring the patient annually thereafter.",
"   </p>",
"   <p>",
"    The evaluation and management of patients with impaired fasting glucose tolerance (FBG within the range of 101 to 125",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    or diabetes (FBS greater than 125",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2312?source=see_link\">",
"     \"Screening for diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     LIPID ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased triglyceride levels have been documented in HIV infection since the late 1980s, before the advent of antiretroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/2,90\">",
"     2,90",
"    </a>",
"    ]. These abnormalities were most often accompanied by low serum levels of HDL, LDL, and total cholesterol. Within the MACS cohort, declines in TC, HDL, and increases in triglycerides were demonstrated at the time of seroconversion in previously uninfected men. Another study showed that treatment-naive patients had low TC and HDL levels and elevated triglycerides, as compared to matched HIV seronegative controls [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With the introduction of HAART, increases in levels of LDL and total cholesterol and further increases in triglycerides have been reported in conjunction with low HDL cholesterol levels [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/2\">",
"     2",
"    </a>",
"    ]. In the study mentioned above, the changes in lipids with the initiation of antiretroviral therapy were not accompanied by changes in diet, dietary intake, weight, or body composition [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/91\">",
"     91",
"    </a>",
"    ]. This atherogenic profile has led to concern regarding potential risk of coronary artery disease in HIV-infected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Definitions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipid abnormalities include hypertriglyceridemia and hypercholesterolemia. Most studies have utilized the US National Cholesterol Education Program III guidelines to define dyslipidemia (total cholesterol &gt;200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    low-density lipoprotein cholesterol &gt;130",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    triglycerides &gt;150",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    high-density lipoprotein cholesterol &lt;40",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    and total",
"    <span class=\"nowrap\">",
"     cholesterol/high-density",
"    </span>",
"    lipoprotein cholesterol ratio &gt;6.5).",
"   </p>",
"   <p>",
"    Laboratory parameters, such as triglyceride levels, are highly variable, prompting some researchers to suggest that two consecutive measurements should be required for improved stringency of diagnostic criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence and severity of lipid abnormalities varies widely depending on the type of HAART and HIV disease stage. Other general factors include the patient&rsquo;s nutritional status and the presence or absence of",
"    <span class=\"nowrap\">",
"     overweight/obesity",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/93\">",
"     93",
"    </a>",
"    ]. While data relating to the impact of diet on lipids in HIV-infected individuals are scant, there are some data that suggest that dietary quality in HIV infection is quite poor, which may contribute to lipid abnormalities.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study demonstrated that the risk of developing the metabolic syndrome was significantly higher in patients with an increasing viral burden, increasing weight, greater BMI, and greater trunk-to-limb fat ratio [",
"      <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/94\">",
"       94",
"      </a>",
"      ]. Another contributor may be genetic alterations in the genes involved in lipoprotein metabolism [",
"      <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/95\">",
"       95",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One retrospective study of 357 HIV-infected and 115",
"      <span class=\"nowrap\">",
"       HIV/HCV-coinfected",
"      </span>",
"      patients receiving ART demonstrated that underlying HCV infection may confer a degree of protection from HAART-related lipid complications [",
"      <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/96\">",
"       96",
"      </a>",
"      ]. Metabolic complications, including hypercholesterolemia, were more common in patients with HIV alone over a 30-month period of observation.",
"     </li>",
"     <li>",
"      A prospective, cross-sectional study compared risk factors associated with the metabolic syndrome in 471 HIV-infected patients to traditional risk factors in subjects in the National Health and Nutrition Examination Survey (NHANES 2001-2002) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/97\">",
"       97",
"      </a>",
"      ]. The overall prevalence of the metabolic syndrome was similar between HIV-seropositive and HIV-seronegative individuals (25 and 26 percent, respectively). However, HIV-infected patients had significantly lower high-density lipoprotein cholesterol, higher triglyceride, and lower glucose levels compared with subjects from the NHANES cohort. In an additional analysis in a substudy of 347 of these individuals, carotid intimal wall thickness and coronary calcium scores, as surrogate markers of CVD, were significantly greater in those with metabolic syndrome than in those without metabolic syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/98\">",
"       98",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Predictors of dyslipidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Predictors of dyslipidemia include family history (genetics), BMI, and lack of physical activity; poor dietary intake may also contribute to atherogenic lipid profiles in patients with HIV.",
"   </p>",
"   <p>",
"    The relation of regional body fat measurements and lipid levels was examined in the Fat Redistribution and Metabolic Changes in HIV Infection (FRAM) study [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/99,100\">",
"     99,100",
"    </a>",
"    ]. Proatherogenic lipid profiles were more common in HIV-infected patients compared with controls, particularly in association with certain fat redistribution patterns (eg, greater visceral and less leg subcutaneous adipose tissue).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Antiretroviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies to evaluate the role of ART in the development of dyslipidemia have been conducted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Protease inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small cohort studies demonstrate that initiation of protease inhibitor therapy is associated with induction of lipid abnormalities, with few exceptions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/101-104\">",
"     101-104",
"    </a>",
"    ]. In vitro and in vivo studies suggested an increased risk associated with specific agents, particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/105,106\">",
"     105,106",
"    </a>",
"    ]. The following patterns have been noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Baseline abnormalities of triglyceride levels increase further on treatment.",
"     </li>",
"     <li>",
"      Baseline HDL levels are often below normal limits and decrease further or remain unchanged.",
"     </li>",
"     <li>",
"      Baseline total cholesterol levels are often at low normal limits and increase to similar values as age-matched HIV-negative controls.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although certain protease inhibitors appear to have a greater negative effect on lipid profiles than others, increases in levels of fibrinogen have been shown to be a class effect [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/107\">",
"     107",
"    </a>",
"    ]. These clinical observations have led to great concern that dyslipidemias in an aging HIV population may have significant implications for the development of cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/29,61,91,108,109\">",
"     29,61,91,108,109",
"    </a>",
"    ]. There are multiple studies that demonstrate an increased risk of coronary artery disease and premature atherosclerosis in HIV-infected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/29,110-116\">",
"     29,110-116",
"    </a>",
"    ]; one of these studies suggested a strong association with duration of PI therapy and increased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/117,118\">",
"     117,118",
"    </a>",
"    ]. However, the overall incidence of myocardial infarction was low in one large observational study of more than 23,000 patients, suggesting that the risk of cardiovascular disease needs to be weighed against the demonstrated benefits of HAART [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/117\">",
"     117",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26650?source=see_link\">",
"     \"Epidemiology of cardiovascular disease and risk factors in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of newly developed protease inhibitors, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    , has not been associated with adverse alterations in lipid profiles. Boosting with low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    (100 mg) increases total cholesterol and triglyceride levels beyond that of unboosted atazanavir [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/119\">",
"     119",
"    </a>",
"    ]. However, when these agents are used in treatment-naive individuals with baseline (pre-HAART) abnormal lipid profiles, no improvement in lipid parameters should be expected. It remains unclear what the impact of the new classes of agents (CCR5 inhibitors and integrase inhibitors) will have on lipid profiles over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Non-nucleoside reverse transcriptase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of non-nucleoside reverse transcriptase inhibitors (NNRTIs) have suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    may have a beneficial effect on lipids [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/120-122\">",
"     120-122",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the 2NN study that compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    for HIV safety and efficacy, a subset analysis was performed to determine the effects of these two NNRTIs on lipid abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/122\">",
"     122",
"    </a>",
"    ]. Of the patients who completed 48 weeks of follow-up (nevirapine n = 417; efavirenz n = 289), the following results were demonstrated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The increase in HDL levels was significantly larger in patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      (43 versus 34 percent).",
"     </li>",
"     <li>",
"      The increase in triglycerides was lower in those patients assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      (20 versus 49 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In ACTG 5095, the metabolic effects of protease inhibitor-sparing ART was assessed in 1147 treatment-naive subjects who were randomly assigned to a triple nucleoside analog regimen",
"    <span class=\"nowrap\">",
"     (ZDV/3TC/ABC)",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    -containing regimens",
"    <span class=\"nowrap\">",
"     (EFV/ZDV/3TC",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     EFV/ZDV/3TC/ABC)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/123\">",
"     123",
"    </a>",
"    ]. Higher, but modest elevations in all lipid parameters (cholesterol, HDL, LDL) were seen in the EFV-containing arms compared with the triple-nucleoside arm. However, the potency of triple nucleoside regimens is no longer considered equivalent to regimens including either an NNRTI, a PI, or a newer agent, and cannot be recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/5/10325?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Triple regimens using nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Nucleoside analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the NRTIs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    is linked to increases in levels of total cholesterol, LDL-C, and triglycerides [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/44\">",
"     44",
"    </a>",
"    ]. Atherogenic lipid profiles are associated with body fat changes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/90\">",
"     90",
"    </a>",
"    ]. Data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    may be associated with an increased risk of CVD in HIV-infected patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26650?source=see_link\">",
"     \"Epidemiology of cardiovascular disease and risk factors in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;A longitudinal study was conducted to determine whether dietary factors may also contribute to alterations in lipid profiles in patients initiating HAART [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/91\">",
"     91",
"    </a>",
"    ]. Pre- and post-protease inhibitor exposure blood samples indicated that antiretroviral agents had a significant effect on lipid profiles over a six month follow-up independent of body changes; dietary factors did not significantly alter these results. The patients in this study did consume high levels of cholesterol and fat, and low levels of fiber, suggesting that the baseline abnormalities may be related to poor quality diet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Screening and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fasting lipid profiles should be checked in patients prior to and six months after initiation of any new antiretroviral regimen. We suggest annual monitoring thereafter if significant abnormalities are not detected.",
"   </p>",
"   <p>",
"    When lipid abnormalities are detected, patients should be evaluated for secondary causes of dyslipidemia (eg, hypothyroidism, obesity, nephrotic syndrome, hypogonadism, poorly controlled diabetes, or use of alcohol, thiazide diuretics, testosterone, and oral estrogen) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/43/26298/abstract/124\">",
"     124",
"    </a>",
"    ]. One caveat is that LDL-C levels cannot be reliably calculated when triglyceride levels are &gt;400",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    unless a directly measured LDL-C test is performed.",
"   </p>",
"   <p>",
"    Patients should generally undergo evaluation and treatment on the basis of existing guidelines for dyslipidemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14856?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\"",
"    </a>",
"    .) However, there are drug interactions that should be avoided due to an interaction between protease inhibitors and specific statins, due to their metabolism by CYP3A. Of the HMG co-reductase inhibitors,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    has the most favorable profile with regards to drug interactions with HIV protease inhibitors. Omega three fatty acids may play a role in the management of high TG and possibly low HDL in patients with HIV. The treatment of dyslipidemia in HIV-infected patients is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44617?source=see_link\">",
"     \"Treatment of HIV-associated lipodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients can have purely lipoatrophy (fat atrophy), fat deposition, or a mixed picture. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Historical background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lipoatrophy involves the loss of subcutaneous fat in the face, arms, legs, abdomen,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      buttocks. Accumulating data suggest that exposure to certain nucleoside analogs is the major factor associated with lipoatrophy, possibly due to NRTI-induced inhibition of mitochondrial DNA polymerase gamma. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Lipoatrophy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fat deposition occurs in the abdomen, cervical-dorsal area (\"buffalo hump\") or in the breasts. Risk factors include increasing age, female sex, and longer duration of ART. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Fat accumulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Body fat, gender, ethnicity, family history, and age and use of protease inhibitors are predictors of insulin resistance. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Insulin resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence and severity of lipid abnormalities varies widely depending on the type of HAART, nutritional status, and HIV disease stage. Individual genetic risk for dyslipidemia may also play a role. Predictors of dyslipidemia include use of protease inhibitors; non-nucleoside reverse transcriptase inhibitors may lead to an improved lipid profile. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Lipid abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no standardized ways to assess lipoatrophy or fat accumulation in the clinical setting at present. All patients should have an initial measurement of height and weight to assess baseline body mass index and then yearly measurements of weight to evaluate changes over time (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Lipoatrophy'",
"      </a>",
"      above). Measures of waist, hip and mid arm or mid thigh circumference may also be helpful in interpreting changes in body shape or BMI.",
"     </li>",
"     <li>",
"      We typically obtain a fasting blood glucose level prior to and six months after initiation of HIV therapy. If there are no abnormalities, we repeat FBGs annually. Patients with evidence of impaired fasting glucose or diabetes should be managed according to standard protocols. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Insulin resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We typically obtain a fasting lipid profile in patients prior to and six months after initiating antiretroviral therapy. If there are no abnormalities, we repeat screening annually. Patients with evidence of hyperlipidemia should be evaluated according to standard protocols. Decisions about treatment should take into consideration potential drug interactions with ART. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Lipid abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/1\">",
"      Grunfeld C, Kotler DP, Hamadeh R, et al. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989; 86:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/2\">",
"      Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003; 289:2978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/3\">",
"      Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/4\">",
"      Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/5\">",
"      Wanke CA. Epidemiological and clinical aspects of the metabolic complications of HIV infection the fat redistribution syndrome. AIDS 1999; 13:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/6\">",
"      Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 2003; 17 Suppl 1:S141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/7\">",
"      Guarino A, Castaldo A, Russo S, et al. Enteric cryptosporidiosis in pediatric HIV infection. J Pediatr Gastroenterol Nutr 1997; 25:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/8\">",
"      Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000; 23:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/9\">",
"      Bacchetti P, Gripshover B, Grunfeld C, et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005; 40:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/10\">",
"      Khara M, Conway B. Morphologic changes in HIV-infected men: sorting fact from fiction. J Acquir Immune Defic Syndr 2005; 40:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/11\">",
"      Mulligan K, Parker RA, Komarow L, et al. Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. J Acquir Immune Defic Syndr 2006; 41:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/12\">",
"      Wohl DA, McComsey G, Tebas P, et al. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis 2006; 43:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/13\">",
"      Jacobson DL, Knox T, Spiegelman D, et al. Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. Clin Infect Dis 2005; 40:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/14\">",
"      Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003; 17:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/15\">",
"      Leitz G, Robinson P. The development of lipodystrophy on a protease inhibitor-sparing highly active antiretroviral therapy regimen. AIDS 2000; 14:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/16\">",
"      Lo JC, Mulligan K, Tai VW, et al. Body shape changes in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/17\">",
"      Heath KV, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001; 15:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/18\">",
"      Lichtenstein KA, Delaney KM, Armon C, et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 2003; 32:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/19\">",
"      Tien PC, Cole SR, Williams CM, et al. Incidence of lipoatrophy and lipohypertrophy in the women's interagency HIV study. J Acquir Immune Defic Syndr 2003; 34:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/20\">",
"      Carr A, Emery S, Law M, et al. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003; 361:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/21\">",
"      Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002; 277:25863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/22\">",
"      Addy CL, Gavrila A, Tsiodras S, et al. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab 2003; 88:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/23\">",
"      Sweeney LL, Brennan AM, Mantzoros CS. The role of adipokines in relation to HIV lipodystrophy. AIDS 2007; 21:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/24\">",
"      Nagy GS, Tsiodras S, Martin LD, et al. Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin. Clin Infect Dis 2003; 36:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/25\">",
"      Ranade K, Geese WJ, Noor M, et al. Genetic analysis implicates resistin in HIV lipodystrophy. AIDS 2008; 22:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/26\">",
"      Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/27\">",
"      Zanone Poma B, Riva A, Nasi M, et al. Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. AIDS 2008; 22:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/28\">",
"      Nasi M, Guaraldi G, Orlando G, et al. Mitochondrial DNA haplogroups and highly active antiretroviral therapy-related lipodystrophy. Clin Infect Dis 2008; 47:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/29\">",
"      Mallon PW, Cooper DA, Carr A. HIV-associated lipodystrophy. HIV Med 2001; 2:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/30\">",
"      Mulligan K, Tai VW, Algren H, et al. Altered fat distribution in HIV-positive men on nucleoside analog reverse transcriptase inhibitor therapy. J Acquir Immune Defic Syndr 2001; 26:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/31\">",
"      Power R, Tate HL, McGill SM, Taylor C. A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals. Sex Transm Infect 2003; 79:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/32\">",
"      James J, Carruthers A, Carruthers J. HIV-associated facial lipoatrophy. Dermatol Surg 2002; 28:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/33\">",
"      Burgess CM, Quiroga RM. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy. J Am Acad Dermatol 2005; 52:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/34\">",
"      Moyle GJ, Lysakova L, Brown S, et al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med 2004; 5:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/35\">",
"      Funk E, Brissett AE, Friedman CD, Bressler FJ. HIV-associated facial lipoatrophy: establishment of a validated grading scale. Laryngoscope 2007; 117:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/36\">",
"      Lichtenstein KA, Ward DJ, Moorman AC, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001; 15:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/37\">",
"      Parker R, Komarow L, Grinspoon K, et al. Baseline and early ontreatment predictors of lipoatrophy at week 64 in a randomized trial of initial antiretroviral therapy therapy: a secondary analysis of A5005s, a substudy of ACTG 384. Antivir Ther 2005; 10(Supp 3):15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/38\">",
"      Mulligan K, Anastos K, Justman J, et al. Fat distribution in HIV-infected women in the United States: DEXA substudy in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2005; 38:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/39\">",
"      McDermott AY, Terrin N, Wanke C, et al. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study. Clin Infect Dis 2005; 41:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/40\">",
"      Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr 2006; 42:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/41\">",
"      Duong M, Petit JM, Piroth L, et al. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/42\">",
"      Domingo P, Matias-Guiu X, Pujol RM, et al. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. AIDS 1999; 13:2261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/43\">",
"      Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2002; 16:2447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/44\">",
"      Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/45\">",
"      Mallal SA, John M, Moore CB, et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/46\">",
"      Dub&eacute; MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005; 19:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/47\">",
"      Sievers M, Walker UA, Sevastianova K, et al. Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse-transcriptase inhibitor-associated lipoatrophy. J Infect Dis 2009; 200:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/48\">",
"      Hammond E, McKinnon E, Nolan D. Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences. Clin Infect Dis 2010; 51:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/49\">",
"      McComsey G, Maa JF. Host factors may be more important than choice of antiretrovirals in the development of lipoatrophy. AIDS Read 2003; 13:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/50\">",
"      Brown TT, Chu H, Wang Z, et al. Longitudinal increases in waist circumference are associated with HIV-serostatus, independent of antiretroviral therapy. AIDS 2007; 21:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/51\">",
"      Podzamczer D, Ferrer E, Sanchez P, et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 2007; 44:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/52\">",
"      Shlay JC, Sharma S, Peng G, et al. Long-term subcutaneous tissue changes among antiretroviral-naive persons initiating stavudine, zidovudine, or abacavir with lamivudine. J Acquir Immune Defic Syndr 2008; 48:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/53\">",
"      Dub&eacute; MP, Komarow L, Mulligan K, et al. Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. J Acquir Immune Defic Syndr 2007; 45:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/54\">",
"      Shlay JC, Sharma S, Peng G, et al. The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 51:298.",
"     </a>",
"    </li>",
"    <li>",
"     Cohen C, Shen Y, Rode R, et al. Effect of nucleoside intensification on prevalence of morphologic abnormalities at year 5 of ritonavir plus saquinavir therapy in an HIV-infected cohort [abstract 683]. In: Program and abstracts of the 9th Conference on Retroviruses and opportunistic infections (Seattle).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/56\">",
"      Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009; 23:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/57\">",
"      P&eacute;rez-Molina JA, Domingo P, Mart&iacute;nez E, Moreno S. The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy. J Antimicrob Chemother 2008; 62:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/58\">",
"      Kuehn EW, Anders HJ, Bogner JR, et al. Hypocalcaemia in HIV infection and AIDS. J Intern Med 1999; 245:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/59\">",
"      Justman JE, Hoover DR, Shi Q, et al. Longitudinal anthropometric patterns among HIV-infected and HIV-uninfected women. J Acquir Immune Defic Syndr 2008; 47:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/60\">",
"      Martinez E, Mocroft A, Garc&iacute;a-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001; 357:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/61\">",
"      Sax PE, Kumar P. Tolerability and safety of HIV protease inhibitors in adults. J Acquir Immune Defic Syndr 2004; 37:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/62\">",
"      Kotler DP. HIV lipodystrophy etiology and pathogenesis. Body composition and metabolic alterations: etiology and pathogenesis. AIDS Read 2003; 13:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/63\">",
"      Brown T, Wang Z, Chu H, et al. Longitudinal anthropometric changes in HIV-infected and HIV-uninfected men. J Acquir Immune Defic Syndr 2006; 43:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/64\">",
"      Hadigan C. Dietary habits and their association with metabolic abnormalities in human immunodeficiency virus-related lipodystrophy. Clin Infect Dis 2003; 37 Suppl 2:S101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/65\">",
"      Hendricks KM, Dong KR, Tang AM, et al. High-fiber diet in HIV-positive men is associated with lower risk of developing fat deposition. Am J Clin Nutr 2003; 78:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/66\">",
"      Despr&eacute;s JP. Health consequences of visceral obesity. Ann Med 2001; 33:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/67\">",
"      Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ 1995; 311:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/68\">",
"      Aldeen T, Wells C, Hay P, et al. Lipodystrophy associated with nevirapine-containing antiretroviral therapies. AIDS 1999; 13:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/69\">",
"      Drechsler H, Powderly WG. Switching effective antiretroviral therapy: a review. Clin Infect Dis 2002; 35:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/70\">",
"      Barreiro P, Soriano V, Blanco F, et al. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 2000; 14:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/71\">",
"      Shlay JC, Bartsch G, Peng G, et al. Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy. J Acquir Immune Defic Syndr 2007; 44:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/72\">",
"      Carr A, Workman C, Carey D, et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 2004; 363:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/73\">",
"      Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85:2402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/74\">",
"      Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/75\">",
"      Bonfanti P, Giannattasio C, Ricci E, et al. HIV and metabolic syndrome: a comparison with the general population. J Acquir Immune Defic Syndr 2007; 45:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/76\">",
"      Jones CY, Wilson IB, Greenberg AS, et al. Insulin resistance in HIV-infected men and women in the nutrition for healthy living cohort. J Acquir Immune Defic Syndr 2005; 40:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/77\">",
"      Tien PC, Schneider MF, Cole SR, et al. Antiretroviral therapy exposure and insulin resistance in the Women's Interagency HIV study. J Acquir Immune Defic Syndr 2008; 49:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/78\">",
"      Mehta SH, Moore RD, Thomas DL, et al. The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons. J Acquir Immune Defic Syndr 2003; 33:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/79\">",
"      Tebas P. Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients: pathogenesis, prevention, and treatment options. J Acquir Immune Defic Syndr 2008; 49 Suppl 2:S86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/80\">",
"      Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13:F63.",
"     </a>",
"    </li>",
"    <li>",
"     Colby-Germinario SP, Cammalleri C, Germinario RJ. L6 myotubes: the effects of antiretroviral protease inhibitors on sugar transport and cellular glucose transporters. 3th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 2001; Abstract 48.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/82\">",
"      Justman JE, Benning L, Danoff A, et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr 2003; 32:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/83\">",
"      Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001; 15:F11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/84\">",
"      Noor MA, Seneviratne T, Aweeka FT, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002; 16:F1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/85\">",
"      Noor MA, Flint OP, Maa JF, Parker RA. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 2006; 20:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/86\">",
"      Lee GA, Rao M, Mulligan K, et al. Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers. AIDS 2007; 21:2183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/87\">",
"      Brown TT, Li X, Cole SR, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 2005; 19:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/88\">",
"      Meininger G, Hadigan C, Rietschel P, Grinspoon S. Body-composition measurements as predictors of glucose and insulin abnormalities in HIV-positive men. Am J Clin Nutr 2002; 76:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/89\">",
"      Gan SK, Samaras K, Carr A, Chisholm D. Anti-retroviral therapy, insulin resistance and lipodystrophy. Diabetes Obes Metab 2001; 3:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/90\">",
"      Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/91\">",
"      Wanke C, Gerrior J, Hendricks K, et al. Alterations in lipid profiles in HIV-infected patients treated with protease inhibitor therapy are not influenced by diet. Nutr Clin Pract 2005; 20:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/92\">",
"      Worm SW, Friis-M&oslash;ller N, Bruyand M, et al. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS 2010; 24:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/93\">",
"      Crum-Cianflone N, Tejidor R, Medina S, et al. Obesity among patients with HIV: the latest epidemic. AIDS Patient Care STDS 2008; 22:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/94\">",
"      Jacobson DL, Tang AM, Spiegelman D, et al. Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr 2006; 43:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/95\">",
"      Tarr PE, Taff&eacute; P, Bleiber G, et al. Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J Infect Dis 2005; 191:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/96\">",
"      Cooper CL, Mills E, Angel JB. Mitigation of antiretroviral-induced hyperlipidemia by hepatitis C virus co-infection. AIDS 2007; 21:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/97\">",
"      Mondy K, Overton ET, Grubb J, et al. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis 2007; 44:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/98\">",
"      Mangili A, Jacobson DL, Gerrior J, et al. Metabolic syndrome and subclinical atherosclerosis in patients infected with HIV. Clin Infect Dis 2007; 44:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/99\">",
"      Currier J, Scherzer R, Bacchetti P, et al. Regional adipose tissue and lipid and lipoprotein levels in HIV-infected women. J Acquir Immune Defic Syndr 2008; 48:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/100\">",
"      Wohl D, Scherzer R, Heymsfield S, et al. The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. J Acquir Immune Defic Syndr 2008; 48:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/101\">",
"      Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/102\">",
"      Mooser V, Carr A. Antiretroviral therapy-associated hyperlipidaemia in HIV disease. Curr Opin Lipidol 2001; 12:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/103\">",
"      Moyle GJ, Baldwin C. Lipid abnormalities during saquinavir soft-gel-based highly active antiretroviral therapy. J Acquir Immune Defic Syndr 1999; 21:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/104\">",
"      Roberts AD, Muesing RA, Parenti DM, et al. Alterations in serum levels of lipids and lipoproteins with indinavir therapy for human immunodeficiency virus-infected patients. Clin Infect Dis 1999; 29:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/105\">",
"      Purnell JQ, Zambon A, Knopp RH, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000; 14:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/106\">",
"      Lee GA, Seneviratne T, Noor MA, et al. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS 2004; 18:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/107\">",
"      Madden E, Lee G, Kotler DP, et al. Association of antiretroviral therapy with fibrinogen levels in HIV-infection. AIDS 2008; 22:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/108\">",
"      Chang ES, Tetreault DD, Liu YT, Beall GN. The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients. J Am Diet Assoc 2001; 101:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/109\">",
"      Echevarria KL, Hardin TC, Smith JA. Hyperlipidemia associated with protease inhibitor therapy. Ann Pharmacother 1999; 33:859.",
"     </a>",
"    </li>",
"    <li>",
"     Mary-Krause M, Cotte L, Partisani M, et al. Impact of treatment with protease inhibitor (PI) on myocardial infarction (MI) occurrence in HIV-Infected men. 8th Conference on Retroviruses and Opportunistic Infections, 2001; Abstract 657.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/111\">",
"      Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998; 351:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/112\">",
"      Depairon M, Chessex S, Sudre P, et al. Premature atherosclerosis in HIV-infected individuals--focus on protease inhibitor therapy. AIDS 2001; 15:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/113\">",
"      Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/114\">",
"      Barbaro G. Cardiovascular manifestations of HIV infection. Circulation 2002; 106:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/115\">",
"      Acevedo M, Sprecher DL, Calabrese L, et al. Pilot study of coronary atherosclerotic risk and plaque burden in HIV patients: 'a call for cardiovascular prevention'. Atherosclerosis 2002; 163:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/116\">",
"      Constans J, Marchand JM, Conri C, et al. Asymptomatic atherosclerosis in HIV-positive patients: A case-control ultrasound study. Ann Med 1995; 27:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/117\">",
"      Friis-M&oslash;ller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/118\">",
"      Friis-M&oslash;ller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17:1179.",
"     </a>",
"    </li>",
"    <li>",
"     Malan N, Krantz E, David N, et al. Efficacy and safety of atazanivir-based therapy in antiretroviral therapy naive HIV-1 infected subjects, both iwth and without ritonavir: 48 week results for AI424-089. Presented at the 13th annual Conference on Retroviruses and Opportunistic Infections, Denver, CO, February 5-8th, 2006; abstract # 107LB.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/120\">",
"      van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/121\">",
"      van der Valk M, Kastelein JJ, Murphy RL, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001; 15:2407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/122\">",
"      van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004; 1:e19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/123\">",
"      Shikuma CM, Yang Y, Glesby MJ, et al. Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095). J Acquir Immune Defic Syndr 2007; 44:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/43/26298/abstract/124\">",
"      Oh J, Hegele RA. HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect Dis 2007; 7:787.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3733 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-115.25.216.6-E05BAE8337-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_43_26298=[""].join("\n");
var outline_f25_43_26298=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORICAL BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ADIPOKINES AND LIPODYSTROPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      LIPOATROPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Nucleoside analogs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Screening and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      FAT ACCUMULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Screening and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      INSULIN RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Definitions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Measures of insulin resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Nucleoside analogs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Screening and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      LIPID ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Definitions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Predictors of dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Nucleoside analogs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Screening and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3733\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3733|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/46/750\" title=\"figure 1\">",
"      Obesity in HIV lipodystrophy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/5/10325?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Triple regimens using nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=related_link\">",
"      Diagnosis of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26650?source=related_link\">",
"      Epidemiology of cardiovascular disease and risk factors in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2312?source=related_link\">",
"      Screening for diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44617?source=related_link\">",
"      Treatment of HIV-associated lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14856?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in primary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_43_26299="Domains ESAS";
var content_f25_43_26299=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F56065&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F56065&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Domains of the supplemented Edmonton Symptom Assessment Scale (ESAS)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Limited activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fatigue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Physical discomfort",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shortness of breath",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lack of well-being",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Problems with appetite",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Feelings of depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anxiety",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nausea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Difficulty sleeping",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weakness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dizziness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Difficulty thinking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Constipation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from:",
"     <br>",
"      Bruera, E, Kuehn, N, Miller, MJ, et al. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 1991; 7:6.",
"      <br>",
"       Walke, LM, Byers, AL, McCorkle, R, Fried, TR. Symptom assessment in community-dwelling older adults with advanced chronic disease. J Pain Symptom Manage. 2006; 31:31.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_43_26299=[""].join("\n");
var outline_f25_43_26299=null;
var title_f25_43_26300="Atypical antidepressants - Doses for treating depression";
var content_f25_43_26300=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F88065&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F88065&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Atypical antidepressants: Doses for treating unipolar major depression",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Usual starting dose",
"        <br/>",
"        (mg per day)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Usual daily dose",
"        <br/>",
"        (mg)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Extreme daily dose",
"        <br/>",
"        (mg)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Agomelatine",
"       </td>",
"       <td class=\"centered\">",
"        25",
"       </td>",
"       <td class=\"centered\">",
"        25 to 50",
"       </td>",
"       <td class=\"centered\">",
"        25 to 50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"4\">",
"        Bupropion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Immediate release",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        200",
"       </td>",
"       <td class=\"centered\">",
"        300",
"       </td>",
"       <td class=\"centered\">",
"        100 to 450",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sustained release",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        150",
"       </td>",
"       <td class=\"centered\">",
"        300",
"       </td>",
"       <td class=\"centered\">",
"        150 to 400",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extended release",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        150",
"       </td>",
"       <td class=\"centered\">",
"        300",
"       </td>",
"       <td class=\"centered\">",
"        150 to 450",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mirtazapine",
"       </td>",
"       <td class=\"centered\">",
"        15",
"       </td>",
"       <td class=\"centered\">",
"        15 to 45",
"       </td>",
"       <td class=\"centered\">",
"        7.5 to 60",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Lower doses are often used for elderly, medically compromised (eg, renal or liver disease), or drug sensitive patients, as well as patients with a lower body mass index. Higher doses may be used for medications that are well tolerated but ineffective at lower doses.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Maximum single dose: 150 mg per day.",
"     <br/>",
"     &Delta; Maximum single dose: 200 mg per day.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Maximum single dose: 300 mg per day in Europe; 450 mg per day in the United States.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Gartlehner G, Thaler K, Hill S, Hansen RA. How should primary care doctors select which antidepressants to administer? Curr Psychiatry Rep 2012; 14:360.",
"      </li>",
"      <li>",
"       Labbate LA, Fava M, Rosenbaum JF, Arana GW. Drugs for the treatment of depression. In: Handbook of Psychiatric Drug Therapy, 6th Ed, Lippincott Williams and Wilkins, Philadelphia 2010, p.54.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_43_26300=[""].join("\n");
var outline_f25_43_26300=null;
var title_f25_43_26301="TNM staging bone tumors";
var content_f25_43_26301=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Definition of TNM for bone tumors other than lymphoma and myeloma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"5\">",
"        Primary tumor (T)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TX",
"       </td>",
"       <td colspan=\"4\">",
"        Primary tumor cannot be assessed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T0",
"       </td>",
"       <td colspan=\"4\">",
"        No evidence of primary tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T1",
"       </td>",
"       <td colspan=\"4\">",
"        Tumor 8 cm or less in greatest dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T2",
"       </td>",
"       <td colspan=\"4\">",
"        Tumor more than 8 cm in greatest dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T3",
"       </td>",
"       <td colspan=\"4\">",
"        Discontinuous tumors in the primary bone site",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"5\">",
"        Regional lymph nodes (N)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NX",
"       </td>",
"       <td colspan=\"4\">",
"        Regional lymph nodes cannot be assessed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N0",
"       </td>",
"       <td colspan=\"4\">",
"        No regional lymph node metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N1",
"       </td>",
"       <td colspan=\"4\">",
"        Regional lymph node metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"5\">",
"        Distant metastasis (M)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M0",
"       </td>",
"       <td colspan=\"4\">",
"        No distant metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        M1",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"4\">",
"        Distant metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        M1a",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"4\">",
"        Lung",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        M1b",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"4\">",
"        Other distant sites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"5\">",
"        Histologic grade (G)",
"        <span class=\"small\">",
"         &bull;",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"5\">",
"        Grade is reported in registry systems by the grade value. A two-grade, three-grade, or four-grade system may be used. If a grading system is not specified, generally the following system is used:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GX",
"       </td>",
"       <td colspan=\"4\">",
"        Grade cannot be assessed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        G1",
"       </td>",
"       <td colspan=\"4\">",
"        Well differentiated - low grade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        G2",
"       </td>",
"       <td colspan=\"4\">",
"        Moderately differentiated - low grade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        G3",
"       </td>",
"       <td colspan=\"4\">",
"        Poorly differentiated - high grade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        G4",
"       </td>",
"       <td colspan=\"4\">",
"        Undifferentiated - high grade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"5\">",
"        Anatomic stage/prognostic groups",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IA",
"       </td>",
"       <td>",
"        T1",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"       <td>",
"        G1, 2 Low grade, GX",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Stage IB",
"       </td>",
"       <td>",
"        T2",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"       <td>",
"        G1, 2 Low grade, GX",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T3",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"       <td>",
"        G1, 2 Low grade, GX",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IIA",
"       </td>",
"       <td>",
"        T1",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"       <td>",
"        G3, 4 High grade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IIB",
"       </td>",
"       <td>",
"        T2",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"       <td>",
"        G3, 4 High grade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage III",
"       </td>",
"       <td>",
"        T3",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"       <td>",
"        G3, 4 High grade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IVA",
"       </td>",
"       <td>",
"        Any T",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M1a",
"       </td>",
"       <td>",
"        Any G",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Stage IVB",
"       </td>",
"       <td>",
"        Any T",
"       </td>",
"       <td>",
"        N1",
"       </td>",
"       <td>",
"        Any M",
"       </td>",
"       <td>",
"        Any G",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any T",
"       </td>",
"       <td>",
"        Any N",
"       </td>",
"       <td>",
"        M1b",
"       </td>",
"       <td>",
"        Any G",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"     * Because of the rarity of lymph node involvement in bone sarcomas, the designation NX may not be appropriate and cases should be considered N0 unless clinical node involvement is clearly evident.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Ewing's sarcoma is classified as G4.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_43_26301=[""].join("\n");
var outline_f25_43_26301=null;
var title_f25_43_26302="Contents: Lipid disorders";
var content_f25_43_26302=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?5/3/5182\">",
"       Cardiovascular Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Lipid disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Lipid disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Evaluation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/31/31222\">",
"           Measurement of serum lipids and lipoproteins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/29/33241\">",
"           Screening guidelines for dyslipidemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pathophysiology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/39/17015\">",
"           Effects of exercise on lipoproteins and hemostatic factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/46/18149\">",
"           Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/25/37274\">",
"           Inherited disorders of LDL-cholesterol metabolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/54/29546\">",
"           Lipid abnormalities after renal transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/41/33430\">",
"           Lipid abnormalities in nephrotic syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/6/6248\">",
"           Lipid abnormalities in patients with chronic kidney disease not requiring dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/56/28550\">",
"           Lipid abnormalities in thyroid disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/45/18138\">",
"           Lipoprotein classification; metabolism; and role in atherosclerosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/38/43621\">",
"           Secondary causes of dyslipidemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/23/10613\">",
"           ATP III guidelines for treatment of high blood cholesterol",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/39/44659\">",
"           Antihypertensive drugs and lipids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/47/35578\">",
"           Approach to the patient with hypertriglyceridemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/55/33656\">",
"           Cholesterol lowering after an acute coronary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/50/19240\">",
"           Clinical trials of cholesterol lowering for primary prevention of coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/38/43626\">",
"           Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/42/19111\">",
"           Compliance with lipid altering medications and recommended lifestyle changes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/34/2601\">",
"           Dietary fat",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/2/39978\">",
"           HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/25/37274\">",
"           Inherited disorders of LDL-cholesterol metabolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/59/3002\">",
"           Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/41/33430\">",
"           Lipid abnormalities in nephrotic syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/6/6248\">",
"           Lipid abnormalities in patients with chronic kidney disease not requiring dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/51/28474\">",
"           Lipid lowering with diet or dietary supplements",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/14/42217\">",
"           Lipid lowering with drugs other than statins and fibrates",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/39/7800\">",
"           Lipid lowering with fibric acid derivatives",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/19/40248\">",
"           Lipoprotein(a) and cardiovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/2/32\">",
"           Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/36/29258\">",
"           Postmenopausal hormone therapy and cardiovascular risk",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/0/33802\">",
"           Statin myopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/56/24453\">",
"           Statin therapy in patients with heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/35/32314\">",
"           Statins: Actions, side effects, and administration",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/63/10230\">",
"           Statins: Possible noncardiovascular benefits",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/5/10329\">",
"           Treatment of drug-resistant hypercholesterolemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/32/10760\">",
"           Treatment of dyslipidemia in the older adult",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/32/14856\">",
"           Treatment of lipids (including hypercholesterolemia) in primary prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/32/26122\">",
"           Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-9C42A1880F-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f25_43_26302=[""].join("\n");
var outline_f25_43_26302=null;
var title_f25_43_26303="Acute eosinophilic pneumonia CT";
var content_f25_43_26303=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute eosinophilic pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 305px; height: 227px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest CT scan of a patient with idiopathic acute eosinophilic pneumonia demonstrating bilateral patchy ground-glass opacities.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven E Weinberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_43_26303=[""].join("\n");
var outline_f25_43_26303=null;
